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INTRODUCTION 
 
Laryngeal cancer is primarily a disease of middle aged men.  It has 
peak incidence in the seventh decade.  It is relatively uncommon in 
women. Worldwide it is the common head and neck cancer. Squamous 
cell carcinoma is the most common type of tumor, comprising 90 percent 
or more of all laryngeal malignancies.  Laryngeal cancer is more common 
in areas with higher levels of social poverty. 
 In the world wide 70 large case control studies covering most of 
the world populations have examined the most common cause of 
squamous cell laryngeal cancer to be tobacco and alcohol.  Occupational 
hazards are associated with the exposure to asbestos, strong inorganic 
acid, cement dust, silica.  Diet rich in salted meat, high total fat content 
has increased risk of laryngeal malignancy.  Intake of plant food, fruits, 
legumes are protective against laryngeal cancer.  The international agency 
for research on cancer (IARC) has evaluated that around 89,000 deaths 
due to this malignancy in males and 12,000 among females worldwide in 
2005.   Survival rates are lower in under developed countries.   
In a study in India the five year relative survival rates were 58.3% 
for glottis cancer and 31.4% for supraglottic cancers.  
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 In France two case series have confirmed that gastroesophageal 
reflux disease is  present in patients with laryngeal cancer.  In a case 
control study conducted in Brazil, showed an increased risk of developing 
squamous cell cancer of head and neck whose first degree relative had 
some type of malignancy. 
 The cardinal symptoms of laryngeal cancer are voice change i.e., 
hoarseness of voice, dysphagia, odynophagia, otalgia, airway obstruction, 
neck mass, weight loss, haemoptysis. 
 Many factors must be considered in determination of optimal 
treatment for a patient. 
1. Age and Sex 
2. General health 
3. Personal preferences 
4. Social circumstances of the patient 
5. Treatment facilities available 
6. Stage of the tumour  
The treatment modalities may be surgery, radiotherapy or 
chemotherapy or combination. 
 Cancer larynx is largely a preventable disease.  The risk of cancer 
is decreased by cessation of smoking and alcohol, as well as reduction in 
carcinogen exposure in occupational settings. The risk diminishes 
dramatically only after 6 years of cessation of smoking and approaches 
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that of non smoker after 15 years.   Early diagnosis is the key to survival 
and cure rate. 
This is a hospital based prospective study to find out the common 
clinical presentation of patients with laryngeal carcinoma with reference 
to the age profile, the symptomatology, disease stage, etiological factors, 
occupational history, histological profile and to determine the treatment 
modalities offered to the laryngeal cancer patients attending ENT OPD at 
GRH., Madurai. 
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OBJECTIVES 
 
1. To estimate the incidence of laryngeal cancer among the patients who 
attend the ENT OPD. 
2. To know the age and sex ratio. 
3. To assess the socio-demographic profile of laryngeal cancer. 
4. To analyze the association of risk factors causing laryngeal cancer. 
5. To know the treatment received by the laryngeal cancer patients at 
Government Rajaji Hospital., Madurai. 
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REVIEW OF LITERATURE 
 
ANATOMY OF LARYNX 
EMBRYOLOGY OF LARYNX 
 The cranial end of respiratory diverticulum develops into the larynx. 
 Epiglottis develops from  caudal end of hypobranchial eminence. 
 Fourth, fifth and  sixth pharyngeal arches give rise to the thyroid, 
cricoid and the arytenoid cartilages. 
 Epiglottis is the last to develop cartilagenous tissue. Branchial 
mesoderm gives rise to muscles of the larynx and have the same nerve 
supply. 
  Hyoid bone is derived from the second and the third branchial  
arches. 
 Epithelial and mesodermal mass between the vestibule and upper  
trachea forms the analogue of vocal cord by 8
th
 week. 
 By 10th week this mass splits sagitaly giving rise to a pair of vocal  
cords.  
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HISTOLOGY 
Mucous membrane of larynx is lined by pseudo stratified ciliated 
columnar epithelium. But in parts where it comes in contact with 
swallowed food it is stratified squamous epithelium. These comprises 
anterior and upper part of  posterior surface of epiglottis and upper parts 
of aryepiglottic fold. Though vocal cords do not come in contact with 
swallowed food they are exposed to some sort of stress during vibration 
of folds and are lined by stratified squamous epithelium. 
Most of the laryngeal cartilages are hyaline and only epiglottis, 
corniculate and cuneiform and apical part of arytenoid are elastic 
cartilages. Increasing age may cause calcification in hyaline cartilage but 
not in elastic cartilages.  
 Larynx acts as a conduit for air, a sphincter and an organ of speech. 
Extending from the tongue to the trachea projects ventrally in between 
the major vessels of the neck. It is covered anteriorly by skin, fasciae and 
muscles which act as depressors of the hyoid bone. It moves with 
deglutition. In adult males it measures 44mm in length with saggital 
diameter 36mm and transverse diameter 43mm. In females it measures 
41mm. It lies opposite to C3-C6 in adult male. 
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SKELETON OF LARYNX 
Larynx is made up of laryngeal cartilages interconnected by 
ligaments and fibrous membranes and moved by a set of muscles. The 
hyoid bone is attached to the larynx. Cricoid, thyroid and epiglottis are 
unpaired cartilages. Arytenoid, cuneiform and corniculate and tritiate are 
paired cartilages. Surface landmarks in relation to the laryngeal 
framework are  
 C3 -Level of body of hyoid and greater cornua 
 C3 – C4 junction – Upper border of thyroid cartilage and 
bifurcation of common carotid artery 
 C4-C5 junction- Level of thyroid cartilage 
 C6- Level of cricoid cartilage 
EPIGLOTTIS STRUCTURE 
It is a thin leaf like structure containing of elastic fibro cartilage 
and projects downwards obliquely behind  tongue and the body of the 
hyoid bone and present in front of the laryngeal inlet. It has a broad and 
round free end  which is occasionally notched in the midline and directed 
upwards. It has a long and narrow stalk which is attached by the thyro 
epiglottic ligament to back of the laryngeal prominence of thyroid 
cartilage  which is below the thyroid notch. Aryepiglottic folds attach the 
sides of epiglottis to the arytenoid cartilages.  Reflections of the upper 
free anterior surface over the pharnyngeal aspect of the tongue and lateral 
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pharyngeal walls form the median and two lateral glossoepiglottic folds 
respectively. On either side of the median glossoepiglottic fold 
depressions called vallecula are present. Hyoepiglottic ligament connects 
the lower part of the anterior surface of epiglottis to the upper border of 
the hyoid bone. Lower part is separated from the thyrohyoid membrane 
by adipose tissue which encloses the clinically important pre epiglottic 
space. The posterior or the laryngeal surface of epiglottis is pitted by 
small mucous glands and is perforated by branches of internal laryngeal 
nerve through which it communicates  with the pre epiglottic space. 
THYROID CARTILAGE 
 It is the largest hyaline cartilage in the larynx. It has two laminae, 
quadrilateral in shape which fuse together in the midline. Due to the 
shallow angle the laryngeal prominence becomes more prominent and the 
vocal cords are long resulting in a more deeper pitched voice. The point 
of junction of upper portion of the laminas forms a V shaped notch called 
the thyroid notch . Their posterior borders are slender and long and form 
the superior and inferior cornua.  
On the external surface of each lamina there is an oblique line 
extending from the superior thyroid tubercle to the inferior thyroid 
tubercle. This line gives attachment to the sternothyroid, thyrohyoid and 
thyropharyngeus. Fibers of stylopharyngeous and palatopharyngeus are 
attached to the thick posterior border.  
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 The superior cornua  is curved upwards and is long and narrow and  
gives attachment to the lateral thyrohyoid ligament. The inferior cornua is 
short and thick and has a facet for articulation with cricoid on the medial 
aspect of its lower end. The angle between the two lamina on the inner 
surface gives attachment to the vestibular folds, vocal ligaments,   
thyroarytenoid, thyroepiglottic and vocalis muscles.  
CRCOID CARTILAGE 
 It is the only laryngeal cartilage which forms a complete ring 
around the airway. It is thicker and stronger and has an anterior arch 
which is narrow and a posterior broad flat lamina.  The arch of the cricoid 
cartilage is narrow anteriorly with vertical height of 5-7mm and expands 
posteriorly to the lamina. On its outer aspect are attached the cricothyroid  
and cricopharyngeus muscles. The arch is separated from the laryngeal 
prominence by the cricovocal membrane.    
 The inferior border of cricoid is attached to the first tracheal ring 
by the cricotracheal ligament. The cricothyroid membrane is attached to 
the medial and lateral part of the superior border of cricoid cartilage. 
Inner surface of the lamina has a median notch on either side of which is 
a facet for articulation with the arytenoids.  
ARYTENOIDS 
 They are paired hyaline cartilages. They articulate with superior 
border of cricoid lamina on its lateral aspect to form the cricoarytenoid 
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joint. Each arytenoid has an apex, two processes and three surfaces and a 
base. It has a  rough and  uneven anterolateral surface .  There is an 
elevation near the apex from which a crest curves backwards then to the 
vocal processes. The upper part of crest gives attachment to the vocal 
ligament. The lower part gives attachment to the vocalis and the lateral 
cricoarytenoid. It has a smooth, triangular and concave posterior surface 
covered by transverse arytenoid. The medial surface of arytenoids in its 
lower edge forms the lateral boundary of the inter cartilagenous part of 
the rimaglottidis. Base articulates with lateral part of  upper border of  
cricoid lamina. The muscular process of arytenoids projects backwards 
and laterally. In front is attached the lateral cricoarytenoid and behind is 
the posterior cricoarytenoid. The vocal ligament is attached to the pointed 
anterior angle. Apex is directed backwards and articulates with 
corniculate cartilage. 
CORNICULATE CARTILAGE/ CARTILAGE OF SANTORINI 
 They are elastic fibro cartilages articulating with apex of arytenoid  
cartilage extending  posteromedially. They are two conical nodules lying 
within the posterior part of aryepiglottic folds. Sometimes they are found 
fused with the arytenoid cartilages.  
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CUNEIFORM CARTILAGE/ CARTILAGE OF WRISBURG 
 They are small rod like with clubbed ends. They are situated in 
each aryepiglottic fold anteriorly and superiorly to corniculate cartilage 
and appear as whitish mucosal elevations. 
JOINTS OF LARYNX  
CRICOTHYROID JOINT 
 It is a synovial joint formed by articulation of the inferior cornua  
of thyroid and the sides of the cricoid cartilage. It has a capsule 
strengthened by fibrous bands. Along a transverse axis passing through 
the cricothyroid joints, cricoid moves on the inferior cornua and also 
glides on the thyroid cornua in different directions. 
CRICOARYTENOID JOINT 
 It is a synovial joint formed by articulation of the base of arytenoid  
with the facets on the lateral parts of the upper border of the cricoid 
lamina. There is a joint capsule strengthened by the posterior 
cricoarytenoid ligament which is medial in position. The arytenoid rotate 
in an oblique axis swinging the vocal process laterally and medially there 
by causing an increase or decrease in the width of the rima glottidis. 
Complex gliding and tipping motion occurs moving the arytenoids 
laterally and downwards.  The forward movement of the arytenoid 
cartilages on the cricoid cartilage are limited by the posterior 
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cricoarytenoid ligaments. The position of the crico arytenoid ligament at 
rest determines the position of denervated vocal cord.  
ARYTENOCORNICULATE JOINTS 
 They are synovial  cartilaginous joints linking the arytenoid and  
corniculate cartilages. 
LIGAMENTS AND MEMBRANES OF LARYNX 
EXTRINSIC LIGAMENTS AND MEMBRANES 
THYROHYOID MEMBRANE 
It is a broad, fibroelastic membrane. Inferiorly it is attached to the 
superior border of the thyroid cartilage and the front of the greater 
cornua. Superiorly attached to the body and the greater cornua of the 
hyoid bone. It moves up behind the body of hyoid forming a bursa in 
between, facilitating  the ascent of larynx during swallowing. It is pierced 
by branches of the superior laryngeal vessels and the internal laryngeal 
nerve on the lateral part. The posterior border of the thyrohyoid 
membrane is formed by the cord like elastic lateral thyrohyoid ligaments. 
Its relations on the inner aspect are the epiglottis and pyriform fossa. 
HYO- AND THYROEPIGLOTTIC LIGAMENTS 
They attach epiglottis to the thyroid cartilage and hyoid bone. 
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CRICOTRACHEAL LIGAMENT 
Lower border of cricoid cartilage is connected to the first tracheal 
ring by the cricotracheal ligament and it continues with the 
perichondrium of the trachea. 
INTRINSIC LIGAMENTS AND MEMBRANES 
QUADRANGULAR MEMBRANE  
 It extends from lateral border of epiglottis to the arytenoid cartilage  
on each side. It has free upper and lower borders. They are poorly 
defined. The upper border slips back forming the aryepiglottic ligament 
which forms the central component of the aryepiglottic fold. It traverses 
the fascial plane of the suspensory ligament of oesophagus posterior 
forming the median corniculo pharyngeal ligament. This ligament exerts 
vertical traction. Its lower border forms the vestibular fold.  
CRICOTHYROID LIGAMENT AND CRICOVOCAL 
MEMBRANE 
 Cricothyroid membrane is mainly elastic and has anterior and 
lateral parts. Anterior part the median cricothyroid ligament and lateral 
part, the cricovocal membrane. 
Cricothyroid membrane extends from upper border of the cricoid 
cartilage to the lower border of the thyroid cartilage. It is thickened in 
front forming the anterior cricothyroid ligament. 
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Cricovocal membrane/ Conuselasticus/ Lateral cricothyroid 
ligament – it is thinner arising from the lower margin of  inner surface of 
cricoid cartilage. It ascends up under the lower border of thyroid cartilage 
and anteriorly attaches to the inner surface of angle of thyroid cartilage. It 
has a free upper end thickened to form the vocal ligament. Its inner 
surface is lined by mucosa and outer surface by the lateral cricoarytenoid 
and thyroarytenoid. 
MUSCLES OF LARYNX 
Larynx has two types of muscles the intrinsic and the extrinsic 
group. The extrinsic group move larynx as a whole during swallowing 
and phonation. These are the sternohyoid, sternothyroid and the 
thyrohyoid and inferior constrictor of the pharynx.  These muscles can 
influence the tone and pitch of voice by raising or lowering the larynx. 
During deglutition geniohyoid moves larynx upwards and anteriorly. 
The cricothyroid, lateral and posterior cricoarytenoid,  transverse 
and oblique arytenoids thyroarytenoid vocalis have attachments within 
the larynx expect for transverse arytenoid which is paired. They lie within 
the thyroid cartilage and only cricothyroid is on the outer aspect.  
The transverse arytenoid has the maximum amount of 
neuromuscular spindles. The muscle mass for adduction is more than that 
for abduction and also even in normal individuals histopathological 
examination reveals degenerative changes in the posterior cricoarytenoid 
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muscle which is the single abductor. Based on the actions they are 
classified as the  Intrinsic muscles 
 Muscles which change size and shape of laryngeal inlet - aryepiglottic 
and oblique arytenoids. 
 Adductors - lateral cricoarytenoid, thyroarytenoid, interarytenoid, 
cricothyroid. 
 Tensors - cricothyroid and thyroarytenoid  
Extrinsic muscles 
 Elevators – mylohyoid, stylohyoid, thyrohyoid, digastric. 
 Depressors – sternothyroid, sternohyoid, omohyoid 
INTERIOR OF LARYNX 
 Larynx extends from the laryngeal inlet to the lower border of 
cricoid, then continues as trachea. It has two sets of  folds projecting into 
the cavity. The vestibular folds /false cords  which cover the median 
aperture rima vestibule. The true vocal cords are present below this and 
the guard the glottis opening or the rimaglottides. The part of larynx lying 
above the glottis is called the supraglottis. It includes the laryngeal 
ventricle, false cords, laryngeal surface of epiglottis, arytenoids and 
laryngeal aspects of the aryepiglottic folds. 
LARYNGEAL INLET 
It is the point of entry between the pharynx and the larynx.  
Anteriorly it is bound by the upper free edge of the epiglottis and the 
16 
 
interarytenoid mucosal fold posteriorly. Either sides are present the 
aryepiglottic folds extending from the side of the epiglottis to apex of the 
arytenoids. 
ARYEPIGLOTTIC FOLD 
 It constitutes fibers from the upper border of quadrangular 
membrane and the oblique arytenoids. Two oval swellings are present in 
the posterior part of aryepiglottic folds representing the underlying 
cuneiform and corniculate cartilages.  
LARYNGEAL INTROITUS 
It is the space between the laryngeal inlet and the false cords. In the  
upper part it is wide and narrows down  below and is high up in the 
anterior part. Posterior surface of epiglottis forms the anterior wall, lateral  
walls by the aryepiglottic folds. Mucosal folds between the arytenoids on  
the posterior part forms the posterior wall. 
MIDDLE PART 
 The larynx is smallest in the middle extending from the rima 
vestibule to the rima glottis. Vestibular folds on either side, the ventricle 
and saccule of larynx are present.  
VESTIBULAR FOLDS AND LIGAMENTS 
 The lower border of quadrangular membrane is thickened to form 
the vestibular ligament. Anteriorly it is attached to the thyroid angle and  
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posteriorly to the arytenoids above the vocal process in the antero lateral 
surface. Vestibular ligaments along with its covering mucosa are called 
the vestibular folds. 
VENTRICLE/SINUS OF LARYNX 
 On both sides of the larynx, aperture between the false and the true  
cords leads to the ventricle of the larynx.  It is fusiform in shape. Above it  
reaches till the laryngeal wall lateral to the false cords. 
SACCULE OF LARYNX 
 Saccule extends forwards form the laryngeal ventricle and lies 
between the vestibular folds and the thyroid cartilage. It  is a cone shaped 
cavity which is directed backwards. It has lot of submucosal mucous 
glands opening into the saccule. Thyroepiglottic muscle seperates the 
saccule from the thyroid cartilage.  The secretions from these mucosal 
glands lubricate the vocal cords and prevent them from infection and 
desiccation. 
VOCAL CORDS 
 They are two in number and are the true cords. They extend 
backward from the middle of thyroid angle to the vocal processes of the 
arytenoids. The mucosa covering vocal cord is thinned out lying directly 
over the vocal ligaments giving it a pearly white colour. Anteriorly the 
vocal cords meet at the anterior commissure. Broyle‘s ligament is formed 
by the fibres of the vocal ligament blending with the perichondrium of the 
18 
 
thyroid cartilage. The glottis consists of the vocal cords, the space which 
lies in a horizontal plane 1 cm inferior to the level of the upper surface of 
the vocal cord, the anterior commissure and the posterior commissure. 
RIMA GLOTTIDIS 
It is an aperture bound anteriorly by the vocal cords and posteriorly 
by the arytenoid cartilages. Vocal ligaments form its anterior inter 
membranous part and vocal process of arytenoids forms the inter 
cartilagenous part. It is the narrowest part of the laryngeal cavity. 
SUBGLOTTIS 
 It lies between the vocal cords above and the lower border of the 
cricoid cartilage below. The shape of the subglottis is elliptical in the 
upper part and circular in the lower part. Subglottis continues with the 
trachea. This is a rare site for origin of cancers but may be involved in the 
glottis cancers. Subglottic malignancy has higher incidence of extra 
laryngeal spread. Due to proximity of cricothyroid membrane and  
postcricoid lymphatics. 
SPACES OF LARYNX 
REINKES SPACE 
 The mucosa over the vocal ligaments is loosely attached to the 
ligaments themselves. There is a submucosal space along most of the 
length of the free edge of the vocal cords extending from the superior 
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arcuate line to inferior arcuate line. Blood vessels and lymphatics are 
almost absent in this space preventing early spread of cancers. 
SUBGLOTTIC SPACE 
This area extends from inferior margin of true cords to the lower 
border of cricoid. It is a potential space filled with fibroelasticsubmucosal  
tissues between mucosa and conuselasticus. The subglottic area does not  
include the vocalis muscle and is limited superiorly at anterior 
commissure by the anterior commissure tendon. 
CRICOID AREA 
 This potential space contains the areolar tissue medial to the 
internal perichondrium of the cricoid. The compartment is situated 
between the subglottic area and the trachea. 
PREEPIGLOTTIC SPACE/SPACE OF BOYER 
 It is bound anteriorly by the thyrohyoid membrane and the thyroid 
cartilage above the thyroepiglottic ligament. Its superior relations are the 
hyoepiglottic ligament and the mucosa of the vallecula. It is posteriorly 
bound by the infrahyoid epiglottis and the thyro epiglottic ligament.  This 
space is laterally continuous with the paraglottic space deep to the 
quadrangular membrane and superior to the ventricle. Cancer on the 
infrahyoid epiglottis spreads readily into the pre epiglottic space.  
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PARAGLOTTIC SPACE 
 This space is situated lateral to the ventricle and the glottis. 
Involvement of this space by malignancy causes fixation of the vocal 
cord and is considered to be the advanced stage of the cancer. It is bound 
anterolaterally by the thyroid cartilage and the cricothyroid membrane, 
superomedially by the quadrangular membrane, inferomedially by the 
conus elasticus and posteriorly by the reflection of the pyriform sinus 
mucosa. It blends with the preepiglottic space anterosuperiorly. 
 The submucosa of the ventricle is continuous with the paraglottic 
space which is bound by the conus elasticus inferomedially, quadrangular  
membrane superomedially and the thyroid ala laterally. Inferolaterally the  
paraglottic space is continuous with the cartilage defect between the 
thyroid and the cricoid cartilage. Tumor involving the ventricle invades 
the paraglottic space and then spreads transglottically. Vocal cord 
tumours which extend deep into the thyroarytenoid muscle invade the 
paraglottic space which later extends to the subglottic space and then 
spreads extra laryngeally. Lateral supraglottic tumours can travel lateral 
to ventricle along the inner surface of the thyroid ala and thus spread 
subglottically. The close proximity of the mucosa of the pyriform sinus to 
the posterior paraglottic space makes this a potential route for spread of 
pyriform sinus malignancy into the endolarynx resulting often in fixation 
of the hemilarynx. 
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SURGICAL ANATOMY 
 
 The larynx is divided into three sites and each of these sites is 
divided into sub-sites. This is done according to the International Union 
Against cancer. 
 
1. SUPRAGLOTTIS 
A. Suprahyoid Epiglottis  
(including tip, lingual & laryngeal surfaces)    Epilarynx  
B. Aryepiglottic fold laryngeal aspect     (Including Marginal Zone) 
C. Arytenoid. 
D. Infrahyoid Epiglottis   Supraglottis 
E.Ventricular bands (False cords) (Excluding Epilarynx) 
 
2. GLOTTIS 
A. Vocal cords 
B. Anterior commissure 
C. Posterior commissure 
 
3. SUBGLOTTIS 
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BLOOD SUPPLY AND LYMPHATIC DRAINAGE 
 Most of the parts of the larynx are supplied by the superior 
laryngeal arteries except for the region around the cricothyroid which is  
supplied by the inferior laryngeal artery. Region around the posterior 
cricoarytenoids is supplied by the posterior branch of the inferior 
laryngeal artery. 
 Superior laryngeal branch of the superior thyroid artery supplies 
the supraglottis. Inferior  laryngeal branch of the inferior thyroid artery 
supplies the subglottis and undersurface of the vocal cords. This 
accompanies the recurrent laryngeal nerve. Some blood supply comes 
from the cricoid branch of the superior thyroid artery.  
Supraglottis – the lymph vessels pierce the thyrohyoid membrane 
and drain into the level II and level III jugulodigastric and 
juguloomohyoid nodes. Ventricular lymphatics also pass through the 
cricothyroid membrane and ipsilateral thyroid gland to the Level III and 
Level IV lymph nodes.  
Subglottis- the lymphatics form three main trunks. One superficial 
trunk pierces the cricothyroid membrane and drains into the delphian 
nodes which inturn drains into the pre and paratracheal and the 
supraclavicular nodes. The two posterolateral trunks penetrate the 
cricotracheal membrane and terminate in the para tracheal node and the 
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superior mediastinum. These nodes drain into the lower deep cervical 
nodes.  
Glottis- This is the watershed area with poor lymphatics. Anterior 
commissure drains into the prelaryngeal nodes. 
 Venous drainage is by the superior and inferior laryngeal veins 
which are the tributaries of the superior and inferior thyroid veins. 
Superior thyroid vein drains into the internal jugular vein. Inferior thyroid 
vein drains into the left brachiocephalic vein. 
NERVE SUPPLY 
 Autonomic -Mucous glands throughout the larynx receive 
parasympathetic secretomotor  fibres via the superior and recuurent 
laryngeal nerves. Postganglionic sympathetic fibres are from the superior 
and middle cervical ganglia. 
Sensory – supraglottis and upper surface of vocal cords are 
supplied by the internal branch of superior laryngeal nerve. Subglotis and 
lower surface of vocal cords are supplied by the reccurent laryngeal 
nerve. 
Motor – all intrinsic muscles except cricothyroid are supplied by 
the recurrent laryngeal nerve. Cricothyroid is supplied by the external 
branch of the superior laryngeal nerve. Extrinsic muscles are supplied by 
the ansacervicalis. 
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ANATOMY OF NECK 
 
LAYERS IN THE ANTERIOR NECK 
- Skin 
- Superficial fascia with platysma, anterior jugular vein, submental  
lymph node, anterior cutaneous nerve. 
- Deep fascia-Above the hyoid bone is single layer in medial plane 
splits to enclose submandibular salivary gland. Between hyoid and 
cricoid- single layer extending below right and left 
sternocleidomastoid muscle. 
- Below cricoid- splits to enclose the suprasternal space. 
STRUCTURES LYING ABOVE THE HYOID BONE 
Mylohyoid muscle overlapped by  
- Anterior belly of digastric 
- Superficial part of submandibular salivary gland 
- Mylohyoid nerve and vessels 
- Submental branch of facial artery 
ANTEROINFERIORLY  
 Hyoglossus muscle with intermediate tendon of digastric and 
bifurcated tendon of stylohyoid.  
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STRUCTURES LYING BELOW HYOID BONE 
INFRAHYOID MUSCLES - sternohyoid, sternothyroid, 
thyrohyoid, superior belly of omohyoid. 
PRE TRACHEAL FASCIA 
 Forms the false capsule of the thyroid gland and suspensory 
ligaments of berry which attach the thyroid gland to the cricoid cartilage. 
Deep to pretracheal fascia lies the thyrohyoid membrane pierced by the 
internal laryngeal nerve and the superior laryngeal vessels 
ANTERIOR TRIANGLES OF THE NECK 
 Bounded medially by the anterior median plane of the neck, 
laterally sternocleidomastoid muscle, superiorly line joining the angle of 
mandible to the mastoid. It is divided into the submental, digastric, 
carotid, muscular triangle by the digastric and the superior belly of the 
omohyoid. 
SUBMENTAL TRIANGLE 
 Bound on each side by the anterior belly of the digastric, base by 
the body of the hyoidbone, floor by the right and the left mylohyoid 
muscle and apex by the chin. 
 Two to four submental lymph nodes and the small submental veins 
join to form the anterior jugular vein. 
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DIGASTRIC TRIANGLE 
 Bound anteroinferiorly by the anterior belly of the digastric, 
postero inferiorly by the posterior belly of  digastric and stylohyoid., 
superiorly by the base of the mandible and the line joining the mandible 
to the mastoid process. Floor is formed by the mylohyoid muscle. 
Contents – anterior part of the triangle. Structures superficial to 
mylohyoid - superficial part of submandibular salivary gland, submental 
artery and the mylohyoid nerves and vessels. Superficial  to hyoglossus-  
submandibular salivary gland, intermediate tendon of the digastric and 
the stylohyoid and the hypoglossal nerve. 
POSTERIOR PART OF THE TRIANGLE 
Superficial structures- lower part of parotid and the external carotid 
artery Deep structures between the internal and the external carotid 
artery- styloglossus, stylopharyngeous, styloid process, glossopharyngeal 
nerve, pharyngeal branch of vagus. 
Deepest  lies the internal carotid artery, internal jugular vein and 
the vagus nerve and the submandibular lymphnodes. 
CAROTID TRIANGLE 
 Anterosuperiorly posterior belly of digastric and the stylohyoid, 
anteroinferoirly superior belly of omohyoid, posteriorly anterior border of 
sternocleidomastoid, roof by the skin, superficial fascia and the deep 
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fascia, Floor by the middle constrictor of the pharynx, inferior constrictor 
of the phaynx and thyrohyoid membrane. 
CONTENTS 
Arteries – common carotid artery with carotid sinus and the carotid 
body, internal carotid artery, external carotid artery with superior thyroid, 
lingual , facial, ascending pharyngeal and the occipital artery. 
Veins – internal jugular vein with tributaries phrenic vein, lingual 
vein, common facial vein. 
Nerves - vagus with superior laryngeal branches, spinal accessory 
nerve, hypoglossal nerve and sympathetic chain. 
MUSCULAR TRIANGLE 
 Bound anteriorly by the anterior median line of the neck from 
hyoid to the sternum, posterosuperiorly superior belly of omohyoid 
posteroinferiorly, anterior border of sternocleidomastoid. The content is 
the infrahyoid muscles. 
POSTERIOR TRIANGLE 
It lies behind the sternocleidomastoid. 
 Bounded anteriorly by the posterior border of the 
sternocleidomastoid, posteriorly by the anterior border of the trapezius, 
inferiorly middle one third of the clavicle and apex on the supra nuchal 
line where the trapezius and the sternocleidomastoid meet. Roof is 
formed by the  platysma, external jugular vein and the posterior jugular 
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vein, supraclavicular, transeverse cutaneous and the greater auricular 
nerves, branches of  occipital, transverse cervical and  suprascapular 
arteries. 
 Floor is formed by the prevertebral layer of the deep cervical fascia 
with the splenius capitis, levator scapulae and  scalenus medius. It is 
divided by the inferior belly of the omohyoid into the large upper 
occipital triangle and the small lower supraclavicular or also called 
subclavian triangle. 
OCCIPITAL TRIANGLE 
Nerves-Spinal accessory nerve. 
Four cutaneous branches of  cervical plexus-they are lesser 
occipital, greater auricular, anterior cutaneous branch of the neck, 
supraclavicular nerve. Muscular branches of the levator scapulae, 
trapezius and the rhomboids.  
Vessels- transverse cervical artery and the vein and occipital artery. 
Nodes – supraclavicular and the occipital nodes. 
SUBCLAVIAN TRIANGLE 
- Lower trunk of the brachial plexus 
- Nerve to serratus anterior 
- Nerve innervating subclavius 
- Suprascapular nerve 
- Suprascapular artery and vein 
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- Lower part of the external jugular vein 
- Transverse cervical artery 
- Supraclavicular nodes 
SUBOCCIPITAL TRIANGLE 
 Bound superomedially by the rectus capitis posterior major and the 
minor, superolaterally by the superior oblique muscle, inferiorly by the 
inferior oblique muscle,. Roof is  mainly formed medially by the dense 
fibrous tissue covered by the semispinalis capitis and laterally by the 
longissmus capitis and the splenius capitis. Floor is formed by posterior 
arch of the atlas. 
 It contains third part of the vertebral artery, suboccipital nerve, 
suboccipital plexus of veins and the suboccipital muscles. 
LYMPHATICS OF NECK 
LEVEL Ia submental – bound superiorly by  symphysis menti, 
inferiorly the hyoid bone and anterior belly of digastric. 
LEVEL Ib submandibular- bound superiorly by the body of the 
mandible, inferiorly posterior belly of  the digastric, medially anterior 
belly of digastric, laterally stylohyoid muscle. 
LEVEL IIa upper jugular- bound superiorly by the lower level of 
bony margin of  the jugular fossa, inferiorly level of the lower part of 
body of hyoid bone, medially by the stylohyoid muscle and laterally by 
the vertical plane defined by the accessory nerve. 
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LEVEL IIb upper jugular-bound superiorly by the lower level of 
jugular fossa, inferiorly by the lower level of hyoid bone, medially by the 
vertical plane defined by the accessory nerve and laterally by the 
posterior border of sternocleidomastoid. 
LEVEL III middle jugular - bound superiorly by the lower level of 
hyoid bone, inferiorly by the horizontal plane along the inferior border of 
the anterior cricoid arch, medially by the lateral border of sternohyoid 
muscle and laterally by the posterior border of the sternocleidomastoid. 
LEVEL IV lower jugular -  bound superiorly by the horizontal 
plane along the inferior border of the cricoid arch, inferiorly by the 
clavicle, medially by the posterior border of the sternohyoid and laterally 
by the posterior border of the sternocleidomastoid. 
LEVEL Va posterior triangle – bound superiorly by the 
sternocleidomastoid and the trapezius, inferiorly by the horizontal plane 
along the inferior border of anterior cricoid arch, medially by the 
posterior border of sternocleidomastoid and laterally by the anterior 
border of trapezius. 
LEVEL Vb posterior triangle (supraclavicular) – bound superiorly 
by the horizontal pane along the inferior border of the anterior cricoid 
arch, inferiorly by the clavicle, medially by the posterior border of 
sternocleidomastoid and laterally by the anterior border of the trapezius. 
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LEVEL VI anterior compartment -  bound superiorly by the hyoid 
bone, inferiorly by the sternal notch, medially by the right common 
carotid artery and laterally by the left common carotid artery. 
LEVEL VII superior mediastinal  – bound superiorly by the sternal 
notch, inferiorly by the innominate artery and both medially and laterally 
by the common carotid artery 
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MALIGNANT LARYNGEAL TUMOURS 
 
Laryngeal carcinoma is the eleventh-most common form of cancer 
among men worldwide and is the second-most common malignancy of 
the head and neck. The primary functions of the larynx involve 
phonation, respiration, and deglutition but it also contributes to taste and 
smell by allowing the movement of air over the special sense organs. 
Thus, loss of laryngeal function affects speech and swallowing and some 
of the senses that allow us to enjoy the world.  
Prevention and early diagnosis of laryngeal carcinoma is the most 
effective means for increasing cure rates and preserving function. 
Fortunately, glottic laryngeal carcinoma, tends to be detected at an earlier 
stage than tumors located at other subsites of the head and neck. 
Nevertheless, the symptoms of laryngeal carcinoma can also be 
nonspecific and may result in a delay of diagnosis. In general, hoarseness 
lasting longer than 3 weeks or odynophagia or dysphagia lasting longer 
than 6 weeks should warrant a referral to an otolaryngologist especially 
for patients older than 40 years with an extensive smoking or drinking 
history. Associated otalgia, stridor and weight loss should also be red 
flags to completely rule out a malignant process. 
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The preoperative evaluation of patients with laryngeal carcinoma 
begins with a thorough history and physical examination in the office 
with subsequent endoscopy and surgical biopsy for tissue diagnosis. Once 
a diagnosis is made, the physician and patient must together formulate an 
individualized plan based on the tumor characteristics as well as the 
patient‘s wishes. 
 Laryngeal cancer is more common in men with an incidence of 6.2 
per 100000 compared to women with an incidence of 1.3 per 100000 
females. It is more common after the age of 40 years. Some areas of the 
world has high incidence (>10/100000) such as Brazil, Hongkong, USA, 
India. Low incidence areas include(<2/100000) Japan, Norway, Sweden. 
 Within the larynx the tumour may arise from the glottis, 
supraglottis or subglottis. Study conducted amongst the western 
population shows increased incidence of glottic tumours, whereas the 
asian population has supraglottic tumours in common. The risk factors 
includes geography, lower socioeconomic strata, smoking, alcohol, 
radiation, occupational exposure of asbestosis, mustard gas, 
formaldehyde. 
 The initial assessment of patients with laryngeal cancer begins with 
a thorough history. Symptoms include hoarseness, dysphagia, chronic 
sore throat, neck mass and referred otalgia. The most common 
presentations are the gradual onset of chronic hoarseness (for glottic 
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tumors), sore throat, dysphagia, or otalgia (for supraglottic tumors). 
Subglottic tumors may have minimal symptoms.  
Patients with reflux laryngitis, heavy smokers, and alcohol 
consumers often have an edematous, irritated larynx and may not 
appreciate a voice change from their usual chronic hoarseness. 
Supraglottic tumors have a more subtle symptoms. Dysphagia and 
odynophagia are more common symptoms and suggest extension to the 
tongue base or to the hypopharynx. Shortness of breath can be due to 
vocal cord fixation or ball-valve effect from a large supraglottic lesion. 
Supraglottic tumors  present in association with evidence of cervical 
metastasis.The risk of occult or evident regional tumor spread from 
supraglottic carcinoma with T1, T2, T3, and T4 tumors is 20%, 40%, 
60%, and 80%, respectively. 
Glottic tumors present  early with voice changes. Dysphagia and 
weight loss occur later.The lack of lymphatic drainage within the lamina 
propria of the vocal folds lymph node spread is uncommon. A mass in the 
neck represents direct extralaryngeal spread through the laryngeal 
cartilage or cervical metastasis and in either case suggests advanced 
disease. Difficulty in breathing (dyspnea or stridor) can occur later with 
glottic tumors and signifies bulky disease, vocal cord fixation, or 
subglottic extension with airway narrowing. Hemoptysis can occur if 
pulmonary involvement is present, but this may be a dangerous sign if the 
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primary laryngeal tumor is ulcerated. Genetics plays a role in the 
development of laryngeal cancer, and this may best be understood as an 
increased susceptibility to the environmental carcinogens. Finally, the 
presence of a squamous cell cancer of the head and neck places an 
individual at risk of approximately a 15% to 20% chance of developing a 
second primary within 5 years of initial diagnosis. 
The patient‘s general condition, social and economic situation, 
plays a role in making treatment decisions. A general medical assessment, 
consists of complete haemogram, blood sugars, hypertension, renal 
parameters, pulmonary status, coronary artery disease. If previous 
myocardial infarction or carotid artery disease further work-up needed 
before definitive therapy for laryngeal Cancer.  
Assessment of a patient‘s motor ability predicts  success with a 
trachea - esophageal Voice  prosthesis. Physical examination is a must 
due to high incidence of synchronous (5% to 8%) and metachronous 
primary lesions, a thorough head and neck examination is carried. Visual 
inspection should be combined with digital palpation of the tongue base, 
particularly if superior extension of a supraglottic tumor is suspected. If 
no evidence of a second primary is found elsewhere in the oral cavity, 
oropharynx, or hypopharynx, direct examination of the larynx can be 
done. 
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The neck is examined for evidence of metastatic disease or direct 
extralaryngeal extension. Bimanual palpation of all regions above the 
clavicles, including the central compartment of the neck, is to be done. 
Loss of the normal laryngeal crepitus during side-to-side manipulation of 
laryngeal cartilages can signify postcricoid involvement of the primary 
tumor and may be associated with complaints of dysphagia by the patient. 
Careful  assessment of the thyrohyoid membrane, thyroid cartilage and 
cricothryoid membrane,  overlying soft tissue of the laryngeal complex 
may provide a more clinically useful assessment of the tumor than any 
advanced imaging analysis. Laryngeal carcinoma most frequently 
metastasizes to nodal levels II, III, and IV in the neck. The term 
‗‗transglottic‘‘ is given to a  tumor from one laryngeal region that crosses 
the glottis in continuity with another  region. Such a lesion must have 
invaded the paraglottic space and, for this reason, is associated with a 
high incidence of neck disease and cartilage invasion. 
 Initial laryngeal evaluation is made by indirect mirror 
laryngoscopy. Mirror laryngoscopy was first performed by the singing 
teacher Manuel Garcia in 1894 with a dental mirror and sunlight. This 
technique affords a clear, two-dimensional image of the larynx. It is 
limited by certain factors There is a small subset of patients who do not 
tolerate complete mirror laryngoscopy. In addition, because the 
protruding tongue is secured with a gloved finger, the larynx may be seen 
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in a non physiologic state. Flexible fiber-optic laryngoscopy, combined 
with stroboscopy, gives a closer look at individual areas and allows for 
video and photographic documentation of any visible pathology in a 
physiologic setting. Patients can visualize the lesion on the monitor and it 
may facilitate their understanding of the disease process. The vocal fold 
movement and movement of the cricoarytenoid joint can be appreciate. 
Making the patient to cough lightly, may help to elucidate arytenoids 
mobility.  
Rigid 70
0
 or 90
0
 endoscopes provide a similar view as with indirect 
mirror laryngoscopy but with added magnification.   
Combined with a stroboscopic light source allows for visualization 
of the mucosal wave and aid in detecting early glottis lesions by changes 
in mucosal wave dynamics. Extrusion of the tongue required for rigid 
endoscopy may place the larynx in a slight nonphysiologic position. The  
strong gag reflex can be solved with practical experience. 
Imaging 
Imaging is a critical adjunct to the physical examination, and not a 
substitute. It can be useful for staging. Imaging can provide valuable 
assessment of anatomic spaces difficult to objectively assess on physical 
examination or by endoscopy (pre-epiglottic space, paraglottic space, 
thyroid cartilage invasion). Imaging may also supplement clinical 
examination information as to the tumor volume and extralaryngeal 
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extension. Furthermore, imaging can assist with surgical planning and in 
the determination of whether or not the primary tumor is amenable to 
resection. 
CT and MRI 
Computed tomography (CT) or magnetic resonance imaging (MRI) 
of the head and neck from the skull base to clavicles are both appropriate 
initial imaging choices. T2-weighted MRI allows for excellent 
visualization of  submucosal spread into the pre-epiglottic and paraglottic 
space. Paraglottic space involvement increases the risk of neck disease 
and cartilage invasion. The minor cartilaginous invasion (staged as T3) is 
now being treated with chemoradiation protocols, through-and-through 
cartilage invasion is an indication for surgical resection of the larynx 
because of the high incidence of chondronecrosis after radiation. 
The role of fused modality positron emission tomography / 
computed tomography (PET/CT) in diagnosing and staging patients with 
primary metastasis and recurrent head and neck cancer is a new concept. 
PET/CT combines the detailed anatomic information of the CT with 
PET‘s ability to detect subtle lesions by alterations in metabolic activity. 
By detection of synchronous or metastatic disease, information provided 
by PET/CT led to changes in planned procedures or sparing of previously 
planned procedure and also helped guide biopsy to metabolically active 
areas in the larynx.  
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Metastatic work-up 
In the  laryngeal carcinoma ,distant spread of tumor is rare .Routine 
work-up for metastatic disease in laryngeal carcinoma is institution 
dependent. Lung, followed by liver, are the most frequent sites of distant 
metastasis and as such chest radiographs and laboratory investigation of 
liver function tests (LFTs) with possible liver ultrasonography has been 
the minimal standard at several institutions. Patients with an abnormal 
chest x-ray (CXR) and those with advanced disease or high clinical 
suspicion may warrant CT of the chest and abdomen. 
Recently, the practice of obtaining a pretreatment PET/CT on 
patients with advanced stage laryngeal carcinomas has become more 
frequent. 
Direct laryngoscopy and biopsy 
Initial assessment of the laryngeal structures is done  using the 
anterior commissure, or Holinger, rigid laryngoscopy. This instrument is 
useful for navigating through and around tumor growth. Once this 
endoscope has been used to fully visualize the relevant structures and 
tumor extent, the larger Dedo laryngoscope may be used. It is must to 
concentrate on the laryngeal extent of the lesion after full assessment for 
synchronous or metachronous  lesions is completed. The site, size and 
extent of the tumour, vocal cord mobility is determined. Full 
panendoscopy should include the hypopharynx (including both piriform 
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sinuses and the postcricoid area) and complete esophagoscopy. The 
larynx is brought into complete view, and a photograph or drawing is 
made of the extent of the lesion. A suspension apparatus is useful at this 
point, particularly if two instruments—one to provide exposure and one 
to perform a biopsy—are needed. The  rigid telescopes may be helpful in 
operative laryngoscopy evaluation of laryngeal tumors, but this technique 
is greatly aided by securing the laryngoscope with a suspension bar. The 
rigid 0
0
, 30
0
, 70
0
 telescopes  can be used during staging. These telescopes 
provide superior visualization of the subglottis, the anterior commissure, 
and the ventricle, which are critical areas that may be difficult to assess 
adequately. 
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HISTOLOGICAL CONFIRMATION OF 
LARYNGEAL CANCER 
 
Currently it is normal to get the specimen for histopathological 
examination by direct laryngoscopy and carried under general 
anaesthesia, which also allows careful direct examination of the tumour. 
Biopsy material should include an adequate amount of the tissue from 
ulcerated areas and elsewhere if practicable. Biopsy should be deep and 
reach necrotic tumor, viable tumor and stroma or muscle to prove the 
presence of an invasive squamous cell carcinoma.  
Biopsies should be obtained from the obvious tumor and any 
additional suspicious areas, particularly on contralateral vocal 
cord,anterior commissure and interarytenoid area. This is needed 
especially if a conservation laryngeal procedure is planned.Squamous cell 
carcinoma accounts for 95% of primary laryngeal cancers. Large lesions 
should be adequately sampled with the biopsy forceps to measure 
invasion below the basement membrane. The biopsy material is important 
on three grounds. First, it helps in the definitive diagnosis of malignancy. 
It is difficult to exclude or diagnose malignancy just by inspection. 
Sometimes even benign looking lesions may have malignancy underneath 
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them. Secondly, identification of the type of the tumour. Thirdly it helps 
to know the degree of differentiation. Sometimes difficulties in diagnosis  
of a malignancy do arise if there is negative biopsy. In such cases the 
biopsy to be repeated. Keratotic lesions yields a nonmalignant 
histopathological diagnosis and often difficult to decide whether such 
lesions will go for malignancy. Miscellaneous condition such as chronic 
laryngitis, tuberculosis, fungal laryngitis, wegeners granulomatosis, 
syphilis gives rise to diagnostic confusion. The histopathological 
classification can be done according to Broders Classification. 
The endolaryngeal lesions are well or moderately differentiated. 
Histologic aggressiveness  is suggested by a poorly differentiated lesion. 
This is not usually found to be predictive of biologic tumor behavior. 
Better predictors are deep and extensive invasion (T stage), microvascular 
invasion, and extracapsular spread from involved lymph nodes.  
Verrucous carcinoma represents an unusual presentation of a well 
differentiated squamous cell carcinoma. This tumor, first described in 
larynx in 1966 by Krause and Perez-Mesa, is known for its locally 
aggressive behavior and is slow growing. Its gross presentation is that of 
a warty, keratotic tumor, most often in the oral cavity. Its second most 
common site is the larynx, where it is always endolaryngeal (glottic or 
supraglottic). This tumor accounts for 1% to 2% of laryngeal carcinomas. 
The lesion is usually exophytic, fungating, and broad based. 
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 Whereas the gross appearance is that of neoplastic disease, 
typically the tumor contains hyperkeratotic squamous epithelium with 
minimal cytologic atypia. The tumor margins seem to be pushing rather 
than infiltrating. 
 Basaloid squamous carcinoma is a variant of squamous cell 
carcinoma that is infrequent and unique. The most   comon site is 
hypopharynx, base of tongue, and supraglottic larynx. This to be 
distinguished from  small cell carcinoma, undifferentiated carcinoma, and 
adenoid cystic carcinoma. This type of laryngeal cancer seems to be more 
aggressive and has worse prognosis than squamous cell carcinoma. 
Preoperative metastatic analysis is necessary with this tumor because of 
its predilection to distant disease. 
Non-squamous tumors of the larynx account for less than 5% of 
laryngeal tumors. They typically arise from salivary gland tissue or 
neuroendocrine cells within the larynx. Among salivary gland tumors, 
adenocarcinoma is the most common, followed by adenoid cystic 
carcinoma and mucoepidermoid carcinoma. The most common sarcoma 
of the larynx is the chondrosarcoma, and the common site is cricoid 
cartilage, particularly the posterior lamina. Tumors derived from neural 
cells include paragangliomas, carcinoid tumors, and oat cell tumors. 
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Staging 
 The staging of laryngeal cancer used in  most of  the world was 
published by the America Joint Committee on Cancer Staging (AJCC) . 
The AJCC was formed in 1959 and announced its recommendations in 
1977. Since then they have periodically updated the staging system. In 
1987 the AJCC merged with the European Union against Cancer, with its 
most recently updated staging system announced in May 2002 (6th 
edition). The changes in the most recent edition of the AJCC staging of 
laryngeal cancer are minimal. Tumors staged T4 are to be divided into 
resectable (T4a) and unresectable (T4b). N staging remains unchanged 
except for the addition of the descriptors U for nodal metastasis to the 
upper neck and L for nodal metastasis to the lower neck. Staging follows 
a similar pattern: Stage IVa disease is advanced resectable disease, stage 
IVb is defined as advanced unresectable disease, and stage IVc is defined 
as advanced distant metastatic disease.  
 An ideal staging system has three purposes. First, it provides the 
clinician with prognostic information for the patient (predictive power). 
Second, it  allows for standardization of reporting methods to compare 
similar patients treated with different modalities. Third, it helps to guide 
the clinician toward a treatment plan.  
Although the AJCC succeeds in fulfilling the first two purposes, it 
does not help stratify patients into treatment groups (ie, organ 
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preservation therapy versus total laryngectomy). For example, some 
patients with stage IV laryngeal (glottic) cancer are still candidates for 
organ-preservation surgery, whereas some patients with stage II laryngeal 
cancer (subglottic) are not. Current staging is dependant on office 
assessment, intra operative assessment, and radiologic evaluation. 
TNM staging of laryngeal carcinoma 
Primary tumor (T) 
TX: Primary tumor cannot be assessed 
T0: No evidence of primary tumor 
Tis: Carcinoma in situ 
Supraglottis 
T1: Tumor limited to one subsite* of supraglottis with normal vocal cord 
mobility 
T2: Tumor invades mucosa of more than one adjacent subsite* of 
supraglottis or glottis or region outside the supraglottis (eg, mucosa of 
base of tongue, vallecula, medial wall of pyriform sinus) without fixation 
of the larynx 
T3: Tumor limited to larynx with vocal cord fixation or invading any of 
the following: postcricoid area, pre-epiglottic tissues 
T4: Tumor invades through the thyroid cartilage or extends into soft 
tissues of the neck, thyroid, or esophagus 
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*Subsites include the following: ventricular bands (false cords), 
arytenoids, suprahyoid epiglottis, infrahyoid epiglottis, aryepiglottic folds 
(laryngeal aspect)  
Glottis 
T1 : Tumor limited to vocal cord(s) (may involve anterior or 
posteriorcommissure) with normal mobility 
T1a : Tumor limited to one vocal cord 
T1b : Tumor involves both vocal cords 
T2 : Tumor extends to supraglottis or subglottis, or with impaired vocal 
cord mobility (T2b) 
T3 : Tumor limited to the larynx with vocal cord fixation 
T4 : Tumor invades through the thyroid cartilage or to other tissues 
beyond the larynx (eg, trachea, soft tissues of neck including thyroid and 
pharynx) 
Subglottis 
T1 : Tumor limited to the subglottis 
T2 : Tumor extends to vocal cord(s) with normal or impaired mobility 
T3 : Tumor limited to larynx with vocal cord fixation 
T4 : Tumor invades through cricoid or thyroid cartilage and/or extends to 
other tissues beyond the larynx (eg, trachea, soft tissues of neck, 
including thyroid, esophagus) 
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Regional lymph nodes (N) 
NX : Regional lymph nodes cannot be assessed. 
N0 : No regional lymph node metastasis. 
N1 : Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest  
Dimension. 
N2 : Metastasis in a single ipsilateral lymph node, more than 3 cm but not 
more than 6 cm in greatest dimension, or in multiple ipsilateral lymph 
nodes, none more than 6 cm in greatest dimension, or in bilateral or 
contralateral lymph nodes, none more than 6 cm in greatest dimension 
N2a : Metastasis in a single ipsilateral lymph node more than 3 cm but 
not more than 6 cm in greatest dimension 
N2b : Metastasis in multiple ipsilateral lymph nodes, none more than 6 
cm in greatest dimension 
N2c : Metastasis in bilateral or contralateral lymph nodes, none more than 
6 cm in greatest dimension 
N3: Metastasis in a lymph node more than 6 cm in greatest dimension 
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In clinical examination, the size of the nodal mass should be 
measured, and allowance should be made for intervening soft tissues. 
Most masses larger than 3 cm in diameter are not single nodes but 
confluent nodes or tumors in soft tissues of the neck. There are three 
stages of clinically positive nodes: N1, N2, and N3.  
The use of subgroups a, b, and c is not required but is 
recommended. Midline nodes are considered homolateral nodes 
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TREATMENT POLICY 
 
 Nearly 95% of laryngeal cancers are treatable. Main causes of 
untreatability is distant metastasis(less than 5%), bad general health, 
advanced tumour which involve all the subsites of larynx, fixed cord, 
with  bilateral  nodes and fixed on one side. In these patients five year 
survival rate is less than 5%.Hence any radical treatment to these patients 
is not justified. 
Treatment plan may be classified into following groups: 
1. CURATIVE INTENT: 
 Surgery 
 Radiotherapy (organ preservation with or without chemotherapy) 
 Surgery with post op radiotherapy or chemoradiotherapy 
2. REHABILITATION 
3. PALLIATION 
 General palliative care, nutrition support  
Tracheostomy 
 Palliative surgery 
 Radiotherapy 
 Chemotherapy 
 Radiotherapy and chemotherapy 
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 Treatment by curative intent depends on the age, performance 
status, treatment option opted by the patient, any previous treatment, 
patients distance from treatment facility, follow up reliability, imaging 
availability, skill of the surgeon and pathologist. 
 The following types of procedures are in use now a days, 
1. VERTICAL PARTIAL RESECTION 
 a. Cordectomy 
 b. Frontal partial laryngectomy 
 c. Lateral partial laryngectomy 
 d. Frontolateral partial laryngectomy 
 e. Extended frontolateral partial laryngectomy 
2. HORIZONTAL PARTIAL RESECTION 
 a. Epiglottectomy 
 b. Supraglottic partial laryngectomy 
 c. Extended supraglottic partial laryngectomy 
3. TOTAL RESECTION 
 a. Total laryngectomy alone 
  b. Total laryngectomy with partial pharyngectomy or partial 
glossectomy 
The operation of neck dissection can be combined with the above 
procedures. 
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TOTAL LARYNGECTOMY: 
 Billroth of Vienna first removed the larynx in 1873.  In those  days  
post op complications like septicemia, spreading cellulitis, mediastinitis, 
haemorhage, shock were severe and none of the patient survived. Later 
two stage procedures was introduced. First tracheostomy was done, after 
this larynx was removed after few weeks. Single stage surgery was 
proposed by Moure and Portmann in 1921, since then surgeons are 
following one stage surgery. 
 The surgery is done under general anaesthesia. The most 
commonly used incision is Gluck-Sorenson incision. Exposure of larynx 
is done by dissecting it out from sternomastoids and carotids, tying the 
vascular bundle. The strap muscle cut low in the neck and contralateral 
thyroid freed from the specimen. The trachea is divided below the tumour 
and tracheostome is fashoined. Removal of larynx from above 
downwards is easy, after cutting the constrictors muscle from the thyroid 
cartilage, preserving adequate mucosa. Closure of pharynx is in the shape 
of I or Y with connell suture. A posterior myotomy will avoid segments 
of spasm. Skin closed in layers over suction drains. 
 Feeding is done by nasogastric tube and regular tracheostomy care  
given. The complications include pharyngocutaneous fistula, which is 
more common in 4 to 10 days post operative days. Others include 
haemorrhage, wound infection, pulmonary and cerebral embolism, 
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tracheal crusting, stomal recurrence, thyroid and parathyroid 
insufficiency Swallowing after total laryngectomy is painful for first few 
days. Nasogastric tube can be removed on day 6.If complication like 
fistula occurs then tube left in situ for 10 days or till the fistula is healed 
well.  
With the help of speech therapist functional rehabilitation of the 
voice to be considered. The patients who underwent total laryngectomy 
can satisfactorily develop oesophageal speech. This is produced by the 
subject charging the esophagus with air and using the vibrations at 
cricopharyngeal level or another level to phonate. Neoglottis can be 
created for voice production with the help of redundant mucosa from the 
post cricoid region. Bloom-Singer valve along with neoglottis improves 
voice production. Electrolarynx can be used for the same purpose. 
 The main disability after total laryngectomy is loss of normal 
voice. As there is no regular air passage through the nose, the subject 
cannot  appreciate the smell and taste of food. The patient should avoid 
swimming. The subject to be careful while taking bath as water should 
not enter tracheostome. As the chest cannot be fixed due to lack of 
closure of larynx, strenuous work and lifting heavy weights not possible. 
Adaptation is good when the age is less than 60 yrs. 
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MANAGEMENT OF METASTATIC NECK 
DISEASE 
 
 The presence of metastatic neck disease is a bad sign. Careful and 
effective treatment will provide the cure. Clinical examination remains 
the first method. Great care should be taken in this analysis. False 
positive and false negative rates are around 20-30 percent. Some necks 
are difficult to examine. Retropharyngeal area lympnodes are unable to 
palpate, unless they are enlarged. Computed tomography have become an 
important tool in analysis of neck lymph nodes. It is more accurate than 
the clinical examination. It has a sensitivity of 84% and specificity of 
83%.Physical examination has senstivity 74% and specificity of 81%.The 
detection of malignant lympnodes is based on the fact that cancer invades 
the lymph node, its size, shape and characteristics change, such that it 
enlarges. Hence centre goes for necrosis. There is rim of inflammation, 
which is seen as rim enhancement on CT. The width of non malignany 
cervical lymphadenopathy is 3 mm up to 3 cm, but  nodes greater than 1 
cm in size on CT may contain metastatic disease. Overall 80 percent 
accuracy achieved  by considering the nodes greater than 1 cm has 
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malignancy in it except at level II and high level III where 1.5 cm size is 
the criteria. 
 MRI of neck, Ultrasound examination of neck and guided  biopsy, 
radionuclide  scan, Positron emission tomography, fine needle aspiration 
cytology can be used in evaluating the metastatic neck disease. 
 The treatment option for N0 neck can be elective surgery, elective 
radiotherapy, elective neck investigation(CT or MRI). Wait and see 
policy can be adopted. Elective neck treatment prevents cancer related 
deaths due vascular or lymphatic spread and produce distant metastasis. 
But there is no evidence to suggest that any decrease in survival by 
delaying neck treatment until nodes become palpable clinically palpable. 
For laryngeal malignancy N0 neck incidence is low. It is widely stated in 
the literature that external beam radiation of approximately 40-50 Gy to 
the clinically NO neck will control the occult metastasis in 90 %  to 95 % 
cases. When the primary tumour is being treated by surgery then neck to 
be treated with elective surgery. If the primary is treated by radiotherapy 
then the same modality can be applied for neck also. 
 The NI neck can be treated surgically, because survival rate is good 
and less extra nodal spread. In this case conservation neck surgery is 
feasible. In palpable neck disease all five levels will be involved and 
should be dissected. The gold standard surgery is modified radical neck 
dissection. Morbidity of neck dissection arises due to level V dissection. 
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The role of radiotherapy is controversial and less preferred to surgery in 
NI neck.  
The N2a and N2b neck represents advanced disease should be 
treated with radical surgery. Modified radical neck dissection can be 
performed. Bilateral and contralateral nodes that is N2c neck is less 
common. Over all occurrence is 5% of head and neck cancers. The 
prognosis depends on size, number of lymph nodes, presence or absence 
of extra capsular spread within the neck and not by the laterality. 
 The presence of massive nodes is less common occurrence. Only 
5% patients present  with  N3 neck .Majority of the patients are incurable. 
May be treated with neck dissection or radiotherapy. 
The contraindications for neck dissections are in whom primary 
tumour is untreatable. Patients who are unfit for surgery due to medical 
ailments, inoperable neck disease and distant metastasis. Locoregional 
control of malignancy is good with chemotherapy and radiotherapy used 
in different combination. 
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NECK DISSECTIONS 
 
 Neck dissection or cervical lymphadenectomy is the systematic 
removal of lymph nodes with their surrounding fibrofatty tissue from the 
various compartments of neck. In 1906 Crile described the radical neck 
dissection. Hayes Martin popularized it. This operation is the gold 
standard by which other operations are judged. 
 The types of neck dissections are: 
 1. Radical neck dissection 
 2. Modified radical neck dissection 
 3. Selective neck dissection 
  a. Supraomohyoid 
  b. Posterolateral 
  c. Lateral 
  d. Anterior compartment 
 when the alteration involves the preservation of one or more non-
lymphatic structure relative to radical neck dissection it is called modified 
radical neck dissection. If alteration involves preservation of one or more 
lymphnode groups relative to radical neck dissection it is called selective 
neck dissection. If the modification involves additional lymph nodes or 
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non-lymphatic structure relative to radical neck dissection is called 
extended radical neck dissection (Eg. Carotid artery, paraspinal muscles, 
hypoglossal nerve, vagus nerve, superior mediastinal lymph nodes). En 
block neck dissection is removal of the primary in continuity with the 
neck dissection, as it avoids harbouring of tumour cells in the intervening 
tissues. 
Neck incisions for unilateral dissections may  be trifurcate or non-
trifurcate. The trifurcate incisions are Hayes Martin, Slaughter, Kocher, 
Schobinger, Crile, Conley. The non –trifurcate  incisions are Mac-Fee, J 
shaped, Hockey stick, Inverted hockey stick, Modified apron, Lahey, 
Modified slaughter. 
For bilateral neck dissection incisions used are Bilateral hockey 
stick, Apron, Modified Apron, Bilateral inverted hockey stick, Modified 
Gluck Sorenson incisions. 
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RADICAL NECK DISSECTION 
   
 The boundaries of dissection involves superiorly inferior border of 
the mandible, Inferiorly clavicle, Posteriorly anterior border of trapezius, 
Anteriorly lateral border of sternohyoid muscle, hyoid bone, contralateral 
anterior belly of digastric muscle. The structures removed are Level I to 
V lymph nodes, spinal accessory nerve, Internal jugular vein and external 
jugular vein, Sternocleidomastoid muscle, omohyoid muscle, cervical 
plexus (sensory branches). Submandibular salivary gland and tail of the 
parotid gland. The indications are;  
 1. Clinicaly positive lymph nodes 
 (a) Previous radiotherapy given (b) Previous neck dissection done. 
 2. Fixed neck mass which becomes mobile with radiotherapy or 
 chemotherapy. 
 3. Nodal involvement other than first echelon group. 
The contraindications are; 
 1. Un controlled cancer of the primary site. 
2. Evidence of distant metastasis 
 3. Unfit for major surgery. 
 4. Mass fixed to cervical spine or brachial plexus or trachea 
 5. Unresectable nodes unchanged by radiotherapy or chemotherapy 
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MODIFIED RADICAL NECK DISSECTION 
 
 The lymph nodes of the neck lie within the specific aponeurotic 
planes which can be carefully dissected with preservation of important 
structure (Spinal accessory nerve, sternocleidomastoid, internal jugular 
vein).Boundaries are similar to radical neck dissection. 
The indications are 
1. Elective neck dissection when there is >25 % risk of occult 
positive nodes and surgery is performed for the primary cancer. 
 2. NI neck when surgery is to be followed by radiotherapy. 
 3. For the lesser involved side when bilateral neck dissection is 
done.  
 Contraindications are similar to that of radical neck dissection. 
The types of modified neck dissection are  
Type I : The Spinal accessory nerve is preserved. Sternocleidomastoid 
and internal jugular vein sacrificed. 
Type II : The Spinal accessory nerve and  internal jugular vein preserved. 
Sternocleidomastoid sacrificed. 
Type III : Boccas functional neck dissection (The Spinal accessory nerve, 
sternocleidomastoid, internal jugular vein preserved) 
In all the three types, lympnodes level I to V removed. 
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SELECTIVE NECK DISSECTIONS 
 
 The suprahyoid neck disection done in N0 and NI neck located in 
first echelon of lymphatic drainage. Boundaries of dissection are 
superiorly inferior border of mandible , inferiorly junction of omohyoid 
with IJV. Anteriorly lateral border of omohyoid and anterior belly of 
opposite digastric. Posteriorly posterior border of sternocleidomastoid 
and cutaneous branches of cervical plexus. Structures removed are lymph 
nodes level I, II, III. In posterolateral neck dissection structures removed 
are suboccipital lymph nodes, retroauricular lymph nodes, lymph nodes 
level II, III, IV and V. In anterior compartment neck dissection 
boundaries are superiorly hyoid bone, inferiorly suprasternal notch and 
lateraly media border of carotid sheath. Structures removed are level VI 
lymph node group (Pretracheal, Paratracheal, Precricoid, Perithyroidal) 
and ipsilateral thyroid lobe. In lateral neck dissection boudaries are 
posterior triangle behind submandibular triangle and midline vertical 
structures anteriorly. Structures removed are levels II, III and IV. 
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COMPLICATIONS 
 
 The most common perioperative complications( within 24 hrs) are 
haemorhage which can be primary and secondary, shock, airway 
obstruction, pneumothorax, air embolism, carotid artery rupture, cervical 
sympathetic chain damage, subcutaneous emphysema and cervical spine 
injury. 
 The post operative complications (After 24 hrs) are air leak, 
secondary hemorrhage, wound infection, fistula formation, flap necrosis, 
wound scarring, peripheral motor nerve damage, internal jugular vein 
rupture, fluid and electrolyte imbalance, pulmonary complications like 
atelectasis, bronchopneumonia.  
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RADIOTHERAPY 
 
 The radiotherapy is defined as the application of radiation to gain 
the therapeutic success. Most commonly used is external beam 
radiotherapy, also called teletherapy. In this beam of radiation is directed 
to the patient from a machine placed outside the body of patient. In 
brachytherapy the radioactive material can be introduced into the tumour. 
 The linear accelerator is the standard megavoltage treatment unit   
used nowadays.  The linear accelerator has, a stream of electrons 
produced by a filament in an electrically charged field is which 
accelerated through a series of wave guides in combination with a 
radiofrequency pulse. This electron beam can  be used for treatment or 
can fall on a target to give a beam of maximum energy between 4 and 20 
MV. 
 To have accuracy of delivery of the external beam radiotherapy the 
patient has to be immobilized perfectly. This can be achieved by moulded 
thermoplastic shells which covers head and neck region. These are placed 
on a fixed frame on  treatment couch. Reference marks situated outside 
the shell. This  allows treatment accuracy for 1-2mm. 
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 The effects of radiation occur  in the non-critical part of  cell but, 
some can occur in the DNA. Ionising events results in single strand 
breakage that can be repairable, where as double strand break leads to 
worse repair. Hence cell death occurs within next cell divisions. Cell 
repair is less beneficial in tumour cells compared to that of normal cells. 
Nearly 95% of the sublethal damage  repair to the cell is completed in 6 
hours. Tumour cells which are more than 100 to 150 microns distance 
from the nearest blood vessel sufferes increasing hypoxia and necrosis. 
The anoxic cells are 2.5 to 3.0 times less sensitive to radiation therapy. 
Cellular hypoxia increases the radioresistant. Bioreductive nitroimidazole 
drugs such as misonidazole, etanidazole, nimorazole can mimic oxygen 
and grater tissue perfusion and can be used as hypoxic cell sensitizers. 
  
RADIOTHERAPY FRACTIONATION 
 
 The correct total dose is a balance between the tumour cell kill and 
effect  of early and late side effects. There are two types of fractionation 
one conventional and the other is unconventional which includes 
hypofractionation, hyperfractionation  and  accelerated fractionation .  
 The conventional fractionation defined as to the use of individual 
treatments(fractions) of 1.8 -2 gray which is given daily for five days a 
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week. Curative doasge is generaly of the range 66-70 gray given in 33-35 
fractions over 6.5 to 7 weeks. In post operative radiotherapy the dosage is 
10% lower in the range og 60 –64 gray given in 30 -32 fractions during 6-
6.5 weeks. 
 The hypofractionation defined as fewer fractions and larger dose 
per fraction. This shorter course decreases the chance of tumour 
repopulation and decreased damaged DNA is repaired. This has property 
of late complications. The courses of treatment which uses larger fraction 
sizes than 2 Gy defined as hypofractionation. The hyperfractionation 
consists of use of smaller fractions(<1.8Gy). The use of smaller fractions 
lessens the risk of late adverse effects. Increase in the overall time tends 
to obviate the efficacy of the treatment. The regimens delivering 50-60 
fractions  throws a heavy burden on treatment. 
 In accelerated  fractionation regimes is  the overall treatment time 
is shortened. The usefulness is obtained by combining acceleration with 
hyperfractionation and treating two or three times per day and allowing 
for six hour gap between fractions. In CHART regime (Continous 
hyperfractionated accelerated radiotherapy) 1.5 Gy per fraction is utilised 
three times daily and continously for 12 days and a total of 54 Gy, 
without any weekend break. 
 The factors determining the effectiveness of radiotherapy on 
tumour control are the total dose which means increasing the dose from 
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66 to 70Gy improves local control by 5%.Concurrent platinum based 
chemotherapy increases overall benefit. The use of  cetuximab helps for 
better tumour control. The cetuximab is a monoclonal antibody against 
the ligand domain of the EGF receptor. The taxanes, taxotere (docetaxel) 
and taxol increases the survival  rate. Delay in the starting treatment, 
treatment interruptions, anaemia, smoking influence the outcome of the 
treatment regime. 
 
IMAGE –MODULATED RADIOTHERAPY(IMRT) 
 
 In conventional radiotherapy we use only two or three fields which 
means a significant dose is absorbed by the tissues between skin and the 
target volume. If many fields are used relative contribution of each field 
lessens and absolute dose in front and behind the target is decreased.  
Relative intensity of individual part of each beam can be changed with 
the help of multileaf collimators. This constitutes IMRT .This helps in 
even coverage of tissue volume and adjacent normal tissues receive less 
dosage. Often seven or more multiple beams are used. Hence larger 
volume of normal tissue gets low-dose radiation. This increases the risk 
of second malignancy.  
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IMAGE-GUIDED RADIOTHERAPY(IGRT) 
 
 Effects to decrease the movement of the patient during treatment is 
very important to get the good result. This is  greatly achieved by IGRT. 
This involves fitting the linear accelerator with CT capability so that  
patient position can be confirmed prior to the treatment. Further linear 
accelerator  is programmed to carry the  necessary shifts in the  patient 
position  during the treatment. 
 
TREATMENT  PLANNING  FOR LARYNGEAL 
CANCER 
 
 The treatment for  glottic tumours TI and TII, N0 is radical 
radiotherapy. Surgery  can be kept as a salvage after radiotherapy. A 
lateral parallel opposed field which is used, with 5 cm(TI) or 6cm(TII) 
square fields  which is centered on the vocal cord. This is one cm below 
the thyroid promontory and anterior to lower border of C5.For TI extends 
from the lower border of hyoid bone  to lower border of cricoid cartilage. 
Usually 10 to 20 degree wedges can be used as missing tissue 
compensators. 
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For TII tumours extending to the supraglottic or subglottic field 
size can be extended. In cases of subglottic extension, paraesophageal 
paratracheal lymphnodes are also included in the field. If anterior 
commissure is involved radiation dose to neck to be increased. 
 Dose prescription, depends on field size,  
1.<36 cm2, 50 Gy in 16 fractions should be treated on  daily basis in five 
fractions a week. 
2.36-42 cm2, 55 Gy in 20 fractions should be treated on daily basis in  
five fractions a week. 
3.>42 cm2, 66-64Gy in 2 Gy per fraction, treated on  daily basis, five 
fractions a week. 
In  the supraglottic growth radical radiotherapy is used in early 
tumours. This  tumour has high incidence of occult lymphatic spread in 
levels I and II. Hence patients need  the elective nodal irradiation  to 
lymph nodes of these levels. This can be obtained by two phase 
technique. In phase I which includes the primary tumour, the entire 
larynx,   pre epiglottic space and the cervical lymph nodes on both sides 
in levels  Ib, II and III in front of   the spinal cord. The phase II included 
are the primary tumour and larynx only. The parallel opposed wedged 
fields can be  used in both  of these cases. The total dose given is 66-
70Gy in 2 Gy for each fraction, treating everyday, for five fractions a 
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week, to macroscopic disease and 44-50 Gy in 2 Gy for each  fraction, 
treating daily for five fractions a week, to the  microscopic pathology.  
 The subglottic growths usually present as locally advanced disease 
which requires surgery and followed by adjuvant radiotherapy. The 
enlarged paratracheal lymphnodes is observed in 50% of cases. The 
radiation port spreads from the thyroid cartilage to the level of mid 
trachea. The dose prescription is of  66 -70 Gy in 2 Gy for each fraction, 
treating  every day , totally five fractions a week.  
 In the locally later stages of the disease of  larynx, stage III and IV 
of glottis, supraglottis and subglottis  can be effectively treated by 
chemoradiation  as an alternate to the surgery as a mode of therapy .The 
target volume involved in this are  the larynx, pre-epiglottic space, 
involved  metastatic lymphnodes and all  the lympnodes in draining area 
which may not be enlarged. In phase I the  primary tumour, the entire 
larynx, pre-epiglottic space and bilateral cervical lymph nodes levels Ib to 
V included in the radiation port. In phase II therapy, the level II and level 
V group of  lymph nodes are included. The dose is of 66-70Gy in 2 Gy 
for each fraction, treating every day, for five fractions a week, to 
macroscopic pathology and 44-50 Gy in 2 Gy for each fraction, treating 
daily, five fractions a week, to microscopic pathology. 
 The post op radiotherapy depends on several pathological factors. 
Presence of extracapsular spread of the nodal disease is considered as 
69 
 
high risk disease. The factors which determine the post op radiotherapy 
are excision margins less than 5 mm, stage III and stage IV, perineural 
invasion, vascular invasion, poor differentiation, more than four nodes 
positive, soft tissue invasion dysplasia, poor differentiation or carcinoma 
in situ at the resection margin. Following laryngectomy in addition to the 
above factors, presence of transglottic disease is an additional risk factor. 
 The potential doubling time for squamous cell carcinoma can be as 
low as less than five days. Accelerated repopulation is observed after 
surgery due to increase in the inflammation and tumour growth factors. 
Hence post op radiotherapy should be initiated within six weeks of 
surgery once healing is completed. The patient who receive post op 
radiotherapy with extranodal disease should be of 63 Gy in 35 fractions. 
 
ADVERSE EFFECTS OF RADIOTHERAPY 
 
 The adverse effects of radiotherapy can be divided into acute and 
late effects. Acute adverse effects defined as the changes in the tissues or 
any symptoms noted within 90 days of initiation of the radiotherapy. The 
commonly used grading system is RTOG acute radiation morbidity 
scoring system. In this classification acute effects classified from grade0 
70 
 
(No change) to grade 4 (severe change). The acute effects most 
commonly seen are  
 1. Mucositis (erythema, fibrinous exudates, membranous) 
 2. Skin changes (erythema, desquamation, hair loss,    
hyperpigmentation) 
 3. Altered taste 
 4. Xerostomia 
 5. Swallowing difficulty 
 6. weight loss 
 The orofacial tissues affected by radiation are salivary glands, 
mucus membrane, taste buds, teeth, mandible, skin. 
 The late adverse effects defined as the changes in the tissues or any  
symptoms which occur more than three months from the start of 
radiotherapy. The RTOG/EORTC late radiation morbidity score is used. 
Mostly late complications develop in first three years. In mucosa we can 
see non healing ulcers. In teeth and mandible osteoradionecrosis is seen 
due to decrease in the production of saliva and also change in chemical 
composition, which is highly acidic. In skin we can see teleangiectasia in 
an atrophic dermis under thinned epidermis. Fibrosis may follow later. 
Due to xerostomia there may be difficulty in swallowing, chewing 
.Cervical spine radiation exposure may lead to L‘hermitte syndrome, foot 
drop, spasticity, weakness, hemiparesis, brown - sequard syndrome. 
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CHEMORADIATION THERAPY 
 
 The most commonly used chemoradiation therapy regimes in the 
treatment of squamous cell carcinoma is formulated emperically. The 
drugs which act against tumour cells was selected and combined with the 
radiotherapy and their administration schedule was selected for safety. 
Different chemotherapy schedules are  
1. ADJUNCTIVE CHEMOTHERAPY: This is the use of cytotoxic 
agents with intent to improve survival before, during or after standard 
local treatment by surgery, radiotherapy or both. 
2. INDUCTION CHEMOTHERAPY (Neoadjunctive, upfront, pre-
emptive chemotherapy) : This is the use of cytotoxic agents before going 
to standard treatment with the intention of improving survival. 
3. CONCURRENT CHEMOTHERAPY (Concomitant chemotherapy) : 
In this the use of cytotoxic agents with the intention of improving 
survival during a course of radiotherapy. Synchronous chemotherapy or 
radiotherapy may precede or follow surgery or can be regarded as 
definitive treatment. 
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4. ADJUVANT CHEMOTHERAPY(Maintainance chemotherapy) : In 
this use of cytotoxic agents following definitive local treatment either 
surgery or radiotherapy to improve survival 
5. PALLIATIVE CHEMOTHERAPY : The use of cytotoxics usually 
single agent, in an attempt to relieve symptoms in an incurable disease. 
This is administered in patients with advanced unresectable tumours. The 
mechanism of action of combined chemotherapy and radiotherapy is, the 
chemotherapy enhances the biological response of cell to radiation by 
DNA damage and cell cycle effect. Helps to overcome the tumour 
resistance to radiotherapy like hypoxia, tumour repopulation. 
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CISPLATIN 
 
 It is potent radio sensitizer and used past many years in the 
treatment of squamous cell carcinoma of head and neck along with the 
radiotherapy. It is an inorganic heavy metal coordination complex. 
Following single IV administration, 90% of the drug is attached to the 
proteins. It gets concentrated mainly in liver, kidneys and intestines. The 
recommended dose is 40 mg/m2 weekly or 100mg/m2 in divided doses 
every three weeks as a single intravenous dose. Mechanism of action is 
inhibition of DNA synthesis, inhibition of transcription elongation by 
DNA, inhibition of repair of lethal damage, radio sensitization of hypoxic 
cells. 
 The toxicities of cisplatin are nephrotoxicity, ototoxicity, 
haematological toxicity, gastrointestinal toxicity and electrolyte 
disturbance. Less common are nuerotoxicity, occular toxicity, 
anaphylactic reactions, alopecia. 
 
 
 
 
74 
 
 
BIOLOGY OF LARYNGEAL CANCER 
 
ENVIRONMENTAL PROMOTERS OF CARCINOGENESIS 
1. TOBACCO : 
 Cigarette smoking acts independently and also synergisticaly with 
alcohol in causation of laryngeal cancer. Relative risk of developing 
laryngeal cancer is 2.4% for smokers who smoke  <7  per day to 16.4% 
for smokers who smoke >25 per day. Cessation of smoking decreases risk 
by 70% after 10 yrs. The burning of tar gives off a methyl cholanthrene 
and benzathrene which are broken down by aryl hydrocarbon 
hydroxylase to carcinogenic epoxides which bind to DNA. Tobacco 
products and betal chronicaly irritate the squamous epithelium to produce 
metaplasia. 
2. ALCOHOL : 
Combined use of alcohol and tobacco increases the risk by 50% 
over the estimated risk, if these factors were considered additive. Dark 
liquors (whisky, rum) have greater organic compounds then light liquors 
(vodka, gin). The risk increases with dark alcohol intake. 
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3. VITAMINES AND MINERALS DEFICIENCY : 
 Several study associate high fruits and vegetables intake decreases 
the risk of laryngeal cancer. This is due to the intake of antioxidants or 
free radical scavenging Vit A,C,E. 
4. OCCUPATIONAL FACTORS : 
 Nickel, mustard gas, asbestos, sulphuric and hydrochloric acid 
exposure is associated with laryngeal cancer. Car mechanics, battery 
plant workers have increased risk. 
5. INFECTION : 
 Human papilloma virus may play a role in laryngeal cancer. 
6. GASTROESOPHAGEAL REFLUX DISEASE : 
7. RADIATION EXPOSURE : 
8. IMMUNO SUPPRESSION : 
Laryngeal cancers are more common in immuno suppresed due to 
HIV or organ transplantation. 
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MOLECULAR GENETICS OF LARYNGEAL 
CANCER 
 
 Laryngeal cancer is due to random accumulation of genetic 
alterations. This is critical for cancer cell survival, which are selected in a 
darwanion manner. Critical molecular alterations for cancer development 
activate genes that promote oncogenesis or inactivate genes that prevent 
oncogenesis. The glutathione S-transferases are responsible for 
detoxification of wide range of xenobiotics. P53 tumour suppressor gene 
mutation seen in cigarette smoking. IL-4 receptors are increased in 
smokers. Protooncogene bcl-2 acts by inhibiting apoptosis. Consistent 
amplification of  11q13 protooncogene is  seen in cancer larynx. The ras 
oncogenes family mutation is seen in tobacco and betel nut users. 
 Over expression of growth factors such as epidermal growth factor, 
platelet derived growth factor, fibroblast growth factor ,vascular 
endothelial growth factor and transforming growth factor alfa is seen. 
 The E6 and E7 regions of high risk HPV types (6,8,33) inativates 
the tumour suppressor gene products p53 and prb potentiating neoplastic 
change and cell immortalization. 
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The extracellular matrix disruption is needed for cancer spread. 
Degradation of this matrix is by matrix metallo proteinases and tissue 
inhibitors both of which  are produced by tumour and imbalance of which 
leads to proteolysis. 
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PATHOLOGY OF LARYNGEAL CANCER 
 
 Squamous cell carcinoma (SCC) is the most common malignancy 
of the larynx.  
Macroscopy 
Laryngeal SCC may present as a flat plaque with a well defined, 
raised edge, or  exhibits a polypoid exophytic appearance, which may 
relate to prognosis. The surface of th 
e tumour is sometimes ulcerated. Tumours, particularly in the 
supraglottic region, frequently show one or more sinuses, which extend 
deeply into the growth. Sometimes these are very narrow and slit-like.  
Histological examination always shows a malignant squamous 
epithelial surface lining the whole sinus or slit, often with areas of 
necrosis and fibrin exudation. These deficiencies of the tumour may be 
related to ischaemia in parts furthest away from the blood supply. In a 
small proportion of cases the tumours may show one or more papillary 
elements. These are most common in the glottic and subglottic regions, 
but are occasionally found in the supraglottic portion of a laryngeal 
neoplasm. 
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MICROSCOPY 
 
 Squamous differentiation, is seen as keratinization with variable 
―pearl‖ formation, and the  invasive growth are needed prerequisite 
features of SCC. Invasion is determined by disruption of the basement 
membrane, and extension into the underlying tissue, which is 
accompanied by the stromal reaction. Angiolymphatic and perineural 
invasion are extra additional signs of cancer. The tumours of larynx are 
traditionally divided into well-, moderately-, and poorly differentiated 
SCC. Well differentiated SCC looks very similar to normal squamous 
epithelium. Moderately differentiated SCC has distinct nuclear 
pleomorphism and mitotic activity, which includes abnormal mitoses; 
there is very less keratinization. In poorly differentiated SCC, immature 
cells are very high, with many typical and atypical mitoses, and less 
keratinization. Although keratinization is seen  in well- or moderately-
differentiated SCC, it should not be taken for consideration as an 
important histological criterion in classifying SCC. Most SCC are 
moderately differentiated, so grading by differentiation is of less 
prognostic value, as compared to pattern of invasion. Tumour growth at 
the invasive part can show an expansive pattern, an infiltrative pattern, or 
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both can be seen. Expansive growth pattern is characterised by large 
tumour islands and well-defined pushing margins and is associated with a 
better prognosis. Infiltrative growth pattern is characterized by scattered  
irregular cords or single tumour cells, with very less defined infiltrating 
margins and is associated with an aggressive course. Invasive SCC is 
almost always has  stromal reaction that consists of desmoplasia with 
deposition of extracellular matrix and multiplication of myofibroblasts . 
Neo vascularization is commonly seen. 
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SUMMARY OF PUBLICATIONS 
 
1. Assessment of Risk Factors in Laryngeal Cancer in India :  
A Case – Control study  
Umesh Kapil, Preeti Singh, Sudhir Bahadur, Sada Nand Dwivedi. 
Asian Pacific Journal of Cancer Prevention Vol 6, 2005  
Abstract and Result 
In the univariate analysis it is observed a lower consumption of 
roots and tubers green leaf vegetable other vegetables and fruits, and 
increased consumption of milk, eggs, meat, tea, alcohol, smoking, 
consumption of  betel leaf   along with tobacco as well as a liking for 
spicy and fried foods emerged as significant positive variables.   There 
was a great difference in the dietary consumption patterns of laryngeal 
cancer patients and controls, which indicates a role for nutritional factors 
in the causation of laryngeal cancer in the Indian population. 
2. TOPOGRAPHICAL DISTRIBUTION OF LARYNGEAL 
CARCINOMA – A STUDY OF FIFTY CASES 
R. Raychowdhury, M.A. Rashid, L. M. Ghosh 
Indian Journal of otolaryngology and head and neck surgery vol.54 
Oct-Dec. 2002. 
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Abstract and Result 
The proportion of Head and Neck Carcinoma affecting the larynx 
also varies – 32.86% in Goa, Daman and Diu (Verma and Sequera, 1979), 
21.54% at Chandigarh (Deyasi et al, 1977), 28% at Ajmer (Yadav et al, 
1986), 7.33% at Patiala (Gupta et al, 1986).  Most international studies 
describe the glottis as  commonest site affected by laryngeal carcinoma, 
based upon study of several investigators (Lederman, 1952; Powell and 
Robin,  1983; Thawley, 1991; Sasakii and Carlson, 1993).  The senior 
author (Chakravarty et al, 1992) found Supraglottic cancer more 
common, as did verma  in 1990. 
3. A study of patient factors and tumor characteristics in malignancy 
of larynx:  A tertiary care center experience Shelly Chadha, Bulbul 
Gupta, Shraddha Jaiwani. 
Journal of laryngology and voice July-Dec.2011 Vol.1 
Abstract and Result 
In this group study, the age range was 26-76 years in males and 35-
68 years in ladies with an average of 52 and 53 years, respectively.  Most 
males were affected in  fifth and sixth decades and females in the sixth 
decade with male-female ratio of 10:2:1 (7:1 in the developed countries).   
They pressed more on that 25 percent were affected in the third and 
fourth decades of life. 
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4. Occupational causes of laryngeal cancer  
JORN OLSEN AND SVEND SABROE 
Journal of Epidemiology and Community Health, 1984, 38, 117–
121. 
Abstract and Result 
Increased risk ratios for laryngeal cancer were found for semiskilled and 
unskilled workers, workers exposed to dust, out of doors workers, drivers, 
and the people working in the cement industries and port industry.  The 
study hypothesis was that exposure to chromium or nickel is the etiology 
in the incidence of laryngeal cancer 
5. Laryngeal Cancer in Women: Tobacco, alcohol, Nutritional, and 
Hormonal Factors Silvano Gallus, Cristina Bosetti, Silvia Franceschi, 
et al. 
Cancer Epidemiology, Biomarkers Prev 2003: 12:514-517 
Abstract and Result 
Laryngeal cancer was strongly associated with cigarette smoking  
(OR = 435.7, 95% CI: 38.2 - 4964.4 for smokers of – 25 cigarettes/day) 
and alcohol drinking (OR = 4.3, 95% ?CI: 0.8-24.1 for  5 drinks/day).  An 
indirect relation was observed for vegetables (OR = 0.3, 95% CI: 0.1-0.9 
for the highest level of consumption), fruit (OR = 0.5, 95%  CI: 0.2-1.3), 
and olive oil (OR = 0.3, 95% CI: 0.1.-0.9).  Reproductive and hormonal 
changes were not consistently associated to laryngeal cancer.  This 
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investigation, was based on a uniquely high number of laryngeal cancers 
in women, which provided definite evidence that cigarettes smoking is 
the very high risk factor for laryngeal cancer in women, accounting for 
78% of cases in this population.  Alcohol and  other selected dietary 
aspects account for – 30% of cases, however menstrual and hormonal 
factors does not appear to have a consistent role in laryngeal 
carcinogenesis. 
6. Fried foods: a risk factor for laryngeal cancer 
C Bosetti, R. Talamini, F.Levi, E.Negri 
British Journal of Cancer 2002, 87, 1230 - 1233 
Abstract and Result 
The role of fried foods on laryngeal cancer risk was studied in a 
case- control study from Italy and Switzerland on 527 cases and 1297 
hospital controls.  A significant rise in the risk was found for high 
consumption of fried meat, fish, eggs and potatoes, with odds ratios of 
1.6, 3.1, 1.9 and 1.9. respectively. 
7. The epidemiology of laryngeal cancer in Brazil 
Victor Wunsch Filho 
Sao Paulo Medical Journal Vol.122 no.5 2004 
Abstract and Result 
The city of Sao Paulo has one of the biggest incidences of 
laryngeal cancer in world and Brazil presents high occurrence, compared 
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with other Latin American countries.  Around 8,000 new cases and 3,000 
deaths by laryngeal cancer occur every year in the Brazilian population. 
Tobacco smoking and alcohol intake, occupational hazards have also 
been linked with the disease, such as asbestos, strong inorganic acids, 
cement dust and free crystalline silica.  Added to this, salted meat and 
total fat intake have been linked to high risk of laryngeal cancer.  
Conversely, several other studies have confirmed the fruits, raw leaf 
vegetables and  the legumes protect against the cancer.  Some research is 
have said a possible association between laryngeal squamous cell 
carcinoma and human papilloma virus (HPV), but this is not universally 
accepted.  Gastroesophageal reflux disease is weakly, but always 
correlated with laryngeal cancer.  Familial cancer clusters, of head and 
neck tumors, seem to increase the risk of laryngeal cancer. 
8. Laryngeal Cancer and Gastroesophageal Reflux Disease:  A Case-
control study  
Michael F. Vaezi, MD,  Ph.D., MSept, Mohammed A. 
The American Journal of Medicine 2006 119, 768-776 
Abstract and Result 
A total of 96 cases were matched to 192 controls.  On univariable 
analysis,  significant risk factors were current smoking, odds ratio (OR) 
5.46 (95% confidence interval ICII.2.59-11.50): alcohol, OR 1.97 
(CI.1.19.3.26): and GERD, OR 1.79 (CI. 1.03-3.11).  On multivariable 
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analysis, only smoking OR 2.11. (CI. I.16-3.85), respectively.  Smoking 
and gastroesophageal reflux disease are significant high risk factors for 
laryngeal cancer and  have an independent incremental risk for laryngeal 
carcinogenesis. 
9. Larynx Preserving Treatments in the Early and Advanced 
Laryngeal Cancers ; A Retrospective Analysis 
Kamian Shaghayeah, Aghili Mahdf 
Journal of Cancer Science & Therapy Vol.2 Issue 1  
Abstract and Result  
In 147 cases, chemo radiotherapy was given for  61 patients.  
Twelve cases were excluded from the analysis because of the treatment 
discontinuity or death.  Fifty eight cases were early-staged disease.  In 
median time of follow up (9.9 months), mean overall survival of the 
patients were 51 months and 37 months in early lesions, and 30 months 
and 17 months in locally advanced tumors, respectively.   
The local control rate was 60% in early-staged  disease and 43.5% 
in locally advanced cancer.  The mean total radiation dose given 
significantly affected the tumor control in chemo radiation group. It 
implies that the radiotherapy or chemo radiation can be  used as an 
appropriate alternative to the  total laryngectomy in  the laryngeal cancer 
patients. 
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10. Cancer of the larynx in Puerto Rico 
Albert Villanueva-Reyes, Ed.D. CCC.S1P 
PRHS Vol 27N0.3 September 2008 
Abstract and Result  
The study showed that the average incidence of laryngeal cancer in 
Puerto Rico was 3.8 & 100,000 from 1997-1998 and 3.5 & 100.000 from 
2001-2002 (-1.07 APC).  Of all these cases (n=848) of laryngeal cancer 
reviewed, 88% were male.  Females were more likely to be diagnosed 
before age 50 than males (p=0.02).  In this study, women had twice the 
increased probability of being alive at the end of the study (OR = 1.97: 
CI:1:14-3.45).  The two most frequent types of single treatments for 
laryngeal cancer were radiation therapy (39%) and surgery (33%). Cases 
of laryngeal cancer are decreasing in Puerto Rico.  Significant differences 
by gender were observed, in  the stage of the disease at the time of 
diagnosis.  Future still studies on medical treatment modalities that can  
better preserve vocal function concurrently with voice therapy are 
recommended for laryngeal cancer patients 
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MATERIALS AND METHODOLOGY 
 
The patients attending the ENT OPD of GRH., Madurai, falling 
into the inclusion criteria will be selected for the study. The study 
subjects will be first administered an informed consent form. After 
explaining the details of the study to the subjects in detail written consent 
will be obtained from those who agree to participate in the study. For 
every individual consenting to participate in the study, a case record form 
will be filled. 
The patients with histopathologically proven laryngeal cancer in 
the inclusion criteria are considered. The common clinical presentation of 
patients, age profile, the symptomatology, disease stage, etiological 
factors, histological profile, family history, occupational history and the 
treatment modalities offered to them will be studied. 
1. The procedures done to examine the larynx are indirect laryngoscopy, 
videolaryngoscopy, direct  laryngoscopy. 
2. Radiological investigations include chest X-ray, CT scan neck and  
chest.   
3.Clinical investigations- Complete haemogram and biochemical profile.                                                                                                  
4.  Histopathological examination of biopsy taken from laryngeal growth. 
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Inclusion criteria: 
1. Proven cases of laryngeal cancer by biopsy and histopathological 
examination. 
2. Patients who have not undergone any treatment for laryngeal cancer 
3. Patients who are in good mental health to give reliable answers for the         
Questionnaire 
4. Patients who are willing for the study. 
 
Exclusion criteria : 
1. Patients who  are on chemotherapy or radiotherapy       
2. Patients with recurrent laryngeal cancer 
3. Patients who have discontinued the treatment 
4. Patients with malignancy in other sites along with laryngeal cancer. 
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RESULTS AND OBSERVATIONS 
 
1. INCIDENCE : 
Our hospital is the highest referral unit in the south Tamil Nadu. It 
covers a total population of twenty five million. Every year on an average 
we get an out patient census of about 25, 58, 614 at our Hospital. It is a 
2518 bedded hospital. At ENT department the census is 83633 per year.  
All  the newly diagnosed laryngeal cancer patients were included in the 
study between July 2013 to June 2014.It was found that the incidence was 
0.135.The most common cancer at our ENT department was laryngeal 
cancer followed by hypopharyngeal cancer.  
 
2. AGE AT DIAGNOSIS : 
AGE (Yrs) MALES FEMALES TOTAL 
31-40 6 - 6 
41-50 10 - 10 
51-60 35 1 36 
61-70 52 3 55 
71-80 6 - 6 
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The peak incidence of laryngeal cancer occurred in the age group 
of sixth to seventh decade of life.48.67% were in the sixth decade,31.85% 
were in the fifth decade. The average age at diagnosing the laryngeal 
cancer was 64years.The males had a mean age of 64.30. and the females 
had a mean age of 65.75.The youngest patient in our study was a male of 
age 36 yrs male and the oldest patient was 80 years old male. Our  
analysis also revealed that  men are diagnosed early compared to women. 
The patients with glottic cancers presented to hospital early compared to 
that of supraglottic cancers. Amongst the males and females supraglottic 
growth predominated. 
 
3. SEX : 
SEX NO. OF PATIENTS 
MALE 109 
FEMALE 4 
TOTAL 113 
 
The laryngeal  cancer is more  common in males 96.46% compared 
to females 3.53%.Reccurrence was not seen in any of our patients. No 
deaths were seen amongst females in our study. The general condition 
was better in females compared  to the males. The adverse effects of the 
chemoradiotherapy was also less prominent in females. 
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4. FAMILY HISTORY: 
 In our study conducted at our hospital none of them had  a family 
history of laryngeal cancer. 
5. OCCUPATION: 
The common occupations in which the most of our  patients 
involved were agriculture, manual laborers, daily wages laborers, factory 
workers, masons, carpenters, tailors. Most of the men at the time of 
diagnosing the laryngeal cancer were not involved in any work due to 
disease morbidity. All the females were house wives. 
6. SOCIO-ECONOMIC GROUP: 
 As our hospital caters to a population which belongs to below 
poverty line, most of the patients are from low socioeconomic strata. The 
Kuppusamy classification was used for the same. 
7. DEMOGRAPHIC DISTRIBUTION:  
 Most of the patients taking treatment at our hospital are from south 
tamil nadu which commonly includes the following districts, Madurai, 
Ramnad, Shivakasi, Theni, Trichy, kanyakumari, Coimbatore. The 
maximum number of patients are from Madurai district  followed by 
Ramnad. Majority of the patients belonged to rural area. 
8. DIETARY HABITS: 
 As diet is an important etiological factor for cancer larynx detailed 
history was obtained.92% of them were non vegetarians. Almost all 
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consumed hot, spicy food. The commonly consumed non vegetarian diet 
was meat followed by chicken, which was baked in reused oil. Amongst 
the vegetables the most commonly consumed was tubers, roots, less of 
green leafy vegetables and fruits. Consumption of dairy products was 
less, compared to hot tea. 
9. OTHER HABITS AND ADDICTIONS: 
HABITS MALE FEMALE 
SMOKING 113 - 
ALCOHOL 113 - 
TOBACC0 72 4 
 
(a) SMOKING: 
 In our study, chronic smoker is one who smokes more than one 
pack per day for the past ten years. All the male patients in our study 
were smokers. None of the female patients had smoking habit. Most of 
them smoked for more than 30 years, ranging from twenty to forty years. 
The average pack-year of smoking was 30.6 years. Beedi smoking was 
more common compared to cigarette smoking. 
(b) ALCOHOL: 
A patient  was considered alcoholic when consumed more than 80 gm of 
alcohol per day for at least 5 years. All the male patients were alcoholic. 
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None of the female patients were alcoholic. Hence in our study all the 
male patients were both smokers and  alcoholics. 
(c) TOBACCO CHEWING WITH BETEL LEAF AND BETEL 
NUT: 
 All the female patients were tobacco chewers along with betel leaf 
and betel nut. Female patients  mostly consumed the same for more than 
25 years.63.71% of the male patients were  tobacco chewers. Male 
patients consumed for more than thirty years. 
10. CLINICAL PRESENTATION: 
SYMPTOMS MALES FEMALES TOTAL 
DIFFICULTY IN 
BREATHING 
38.99% 1.76% 40.76% 
VOICE CHANGE 36.27% 0.88% 37.16% 
DYSPHAGIA 9.72% 2.65% 12.38% 
NECK 
SWELLING 
7.97% 1.76% 9.73% 
 
A. Difficulty In Breathing : The most common symptom with which 
patients presented to us was difficulty in breathing, stridor. 40.76% of the 
patient presented with stridor. Amongst them were 38.99% males and 
1.76% were females. 
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B. Change of voice : Next common symptom of presentation was change 
of voice. This was seen in 37.16% of the patients. Most of them were 
males.0.88% females and 36.27% were males.  
C. Dysphagia : 12.38% patients had dysphagia. This was mostly seen in 
supraglottic growth rather than the glottic growth  
D. Swelling in the neck : Swelling in the neck was the main complaint 
for  9.73%of patients 
E. Pain : Pain in the ear was noticed in minority of the patients. 
F. Cough and throat irritation : Minority of the patients had cough and 
throat irritation. 
G. Anorexia, Loss of weight : This was seen in all the patients. 
11. CLINICAL EXAMINATION: 
 On general physical examination there was mild palor 26% of 
patients. Ten patients who had supraglottic growth complained of 
haemoptysis. Icterus was observed in two patients.  
Almost 2/3 of the patients were cachectic. They had significant 
weight loss in recent past. The weight loss was also rapid.35% of the 
patients were bed ridden before coming to the hospital. There was no 
generalized lymphadenopathy or edema noted. Fever was present in 11 
patients due to cough with expectoration. 
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12. SYSTEMIC EXAMINATION: 
 In all our patients ststemic examination was normal. No gross 
abnormality detected.35% of the patient had crepitations in their chest. 
13. INVESTIGATIONS: 
A. COMPLETE HAEMOGRAM : 
All the patients admitted at our hospital were investigated with 
complete haemogram which included haemoglobin, total count, 
differential count, erythrocyte sedimentation, renal parameters, liver 
function tests, random blood sugar level. 26% of  patients had 
haemoglobin less than 10 gm% .In all the patients total count and 
differential count was  near normal. All the patients had liver and renal 
function tests within normal limit.  
B. CHEST X-RAY : 
 Chest X-ray was obtained in all the patients. All the females had 
normal chest X-ray. Amongst the males 26% had emphysematous 
changes. No mediastinal widening noted. No other significant 
abnormality detected in chest x-ray. 
C. COMPUTERISED TOMOGRAPHY OF NECK : 
 CT NECK was obtained in all our patients both axial and coronal 
cuts with and without contrast. Sagital reconstruction was done in some 
patients. This helps to know the tumour extent, involvement of the 
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lymphnodes, invasion of cartilage, invasion of oropharynx and 
hypopharynx. 
D. ABDOMINAL ULTRASONOGRAPHY : 
 Abdominal USG done in all the cases to know for the distant 
metastasis.None of our patients had metastasis in the liver. 
E. VIDEOLARYNGOSCOPIC EXAMINATION : 
 This is an office procedure done under local anaesthesia, the 
patient in sitting posture in barking dog position. A 30 degree and 70 
degree Hopkins rod passed into the oral cavity, oropharynx and larynx. 
The three parts of the larynx examined. All the patients were subjected to 
this. The different types of growth seen are proliferative, ulcero 
proliferative and ulcerative type. Involvement of the different subtypes of 
the larynx studied.  
1. GROSS TYPE OF GROWTH : Most of the tumours were proliferative in  
nature, later followed by ulceroproliferative type 
2. TOPOGRAPHICAL REPRESENTATION: The most common sub site 
involved was supraglottis. Later followed  by glottis. In our study we did 
not have any subglottic growth. In the supraglottic the most common 
subsite was aryepiglottic folds, followed by false vocal cords, arytenoids 
and epiglottis. 
3. MOVEMENT OF THE TRUE VOCAL CORDS: Most of the patients 
had true vocal cords fixity 
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SITE MALE FEMALE TOTAL 
B/L  SUPRAGLOTTIC 38 2 40 
RIGHT SUPRAGLOTTIC 19 1 20 
LEFT SUPRAGLOTTIC 22 - 22 
B/L VOCAL CORDS 8 - 8 
RIGHT VOCAL CORD 11 1 12 
LEFT VOCAL CORD 11 - 11 
SUB-GLOTTIS - - - 
 
F. DIRECT LARYNGOSCOPYC EXAMINATION AND BIOPSY 
 To obtain the tumour tissue for his to pathological examination 
biopsy obtained from the growth and sent for study. All the patients had 
squamous cell carcinoma as the histological diagnosis. Broders 
classification was used. Three types of seen.  
They are well differentiated, moderately differentiated and poorly 
differentiated types. 
HISTOPATHOLOGY MALE FEMALE TOTAL 
WELL.DIFF 43 1 44 
MOD.DIFF 58 2 60 
POORLY.DIFF 8 1 9 
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 In our study most of our patients had moderately differentiated 
squamous cell carcinoma, constituting 53.09%.Well differentiated SCC 
was seen in 38.93% and poorly differentiated seen in 7.96%.Amongst the 
females two patients had mod diff SCC and one  each patient had  well 
differentiated and poorly differentiated SCC. 
14. CLINICAL STAGING: 
T STAGING: 
T STAGING MALE FEMALE TOTAL 
T 1 1 - 1 
T 2 21 - 21 
T 3 85 4 89 
T 4a 2 - 2 
T 4b - - - 
N STAGING: 
N STAGING MALE FEMALE TOTAL 
N0 55 - 55 
N 1 33 2 35 
N 2a 12 1 13 
N 2b 5 - 5 
N 2C - -  
N 3 4 1 5 
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TNM STAGING: 
TNM MALE FEMALE TOTAL 
STAGE 0 - - - 
STAGE I 1  1 
STAGE II 14 - 14 
STAGE III 71 2 73 
STAGE IVa 18 1 19 
STAGE IV b 5 1 6 
STAGE IV C - - - 
 
 For clinical staging of the laryngeal cancer AJCC used. The TNM 
staging was used, where T stands for tumour, N for lymph nodes 
metastasis and M for distant metastasis. Most of our patients were in T3 
.Lymph nodes most commonly involved was N0.None of our patients had 
distant metastasis. The most common staging was stage III. 
15. TREATMENT : 
The different modalities of treatment offered to our patients at our 
hospital are surgery, radiotherapy and chemotherapy often in 
combinations. Nearly  half of our patients came to us with stridor and 
emergency tracheostomy was performed.  Few of our patients had 
difficulty in swallowing who were unable to take oral diet.In such 
patients feeding jejonostomy was performed. Patients initially evaluated 
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for operability and for chemo radiotherapy. First modality of treatment 
offered to our patients was chemoradiotherapy as we had the most of the 
patients from stage III and Stage IV. Surgery was not opted in any of our 
patients. 
A) EMERGENCY TRACHEOSTOMY: 
TRACHEOSTOMY MALE FEMALE TOTAL 
DONE 51 1 52 
NOT DONE 58 3 61 
 
 Chemotherapy as a single modality of treatment was given in very 
few patients who were unfit for surgery and radiotherapy. Otherwise 
usually combined with the radiotherapy.  
In significant minority of patients received only palliative 
chemoradiotherapy due to late stage of disease and moribond  health 
status. 
B) CHEMORADIOTHERAPY: 
 At our hospital for radiotherapy we use Cobalt-60 radiation unit. A 
Cobalt-60 machine uses a radioactive isotope that produces gamma 
photons as the source decays. The cobalt source has a half-life of 5.27 
years and should be replaced about every five years. The focus to skin 
distance for a cobalt machine is usually 80cm. The patient‘s dose for 
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treatment using the Cobalt-60 machine is calculated using several factors. 
The daily dose rate available from the cobalt must be known.  
The amount of centigray or Gray per fraction, the depth of the 
tumor, the size of the field and the daily dose rate must all be entered into 
the equation that will determine the time of the treatment. The only way 
we can regulate the amount of the dose from the cobalt machine is by 
varying the length of time the machine is on. The concurrent 
chemoradiotherapy was offered to most of our patients. 
TREATMENT GIVEN : 
TREATMENT MALE FEMALE TOTAL 
CONCURRENT CHEMORT 94 3 97 
PALLIATIVE RT 10 - 10 
CHEMOTHERAPY 5 1 6 
 
 The tumoricidal dose of radiotherapy for therapeutic purpose used 
was 6000Cgy for 6 weeks. Five days a week.200 Cgy per fraction. The 
palliative radiotherapy dose was 4800 Cgy for 16 fractions. Each fraction 
of 300 Cgy.  
The commonly used chemotherapy at our hospital is cisplatin, 
methotrexate and 5-flurouracil.The recommended doses of cisplatin is 
40mg/m2 weekly or 100mg /m2 in divided doses every 2 weeks as a 
single intravenous dose. The methotrexate is used in the dose of  
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500mg/m2 given on a weekly basis for 2 weeks. The 5-flurouracil is used 
in the dose 450-600 mg/sq.meter IV weekly, for 2 weeks. 
16. ADVERSE EFFECTS OF CHEMORADIOTHERAPY: 
 The acute side effects pertaining to skin changes were seen in all 
the patients. The confluent moist desquamation and moderate edema was 
seen in 62 % of cases. Mucositis was yet another condition seen in all the 
patients .All most all of our patients had severe pain. They were 
prescribed narcotics to treat the pain. Majority of patients had thick 
saliva, altered taste and difficulty in swallowing. Mild to moderate hair 
loss was observed in most of our patients. Loss of sense of smell was also 
seen in minority of patients and was severe in tracheostomised patients. 
17. FOLLOW-UP 
 In our study we had 113 patients. Four patients died during the 
study period. six patients did not complete the treatment as they 
absconded. For four patients radiotherapy was with held to improve 
haemoglobin status. Five patients lost the follow up.  After completion of 
treatment follow up was done every month for first  three months.  
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DISCUSSION 
 
 Cancer of larynx causes great misery to the patient due to 
development of difficulty in speech and swallowing which are the basic 
need in day today life of any individual.  
 The mean age of laryngeal cancer patients in our study was 65 
years. These results were consistent with studies conducted by Shelly 
Chadha Et al at Delhi and study at Puerto Rico by Albert Villanueva. In  
present study laryngeal cancer predominantly present in the males. It has 
been reported in earlier studies that there is marked male preponderance. 
 As our study was conducted at a government hospital where 
patients from low socioeconomic strata are in major numbers. According 
to Kuppusamy classification they fall in class V. Due to their low socio-
economic status, less education qualification, they have less purchasing 
power. Most of our patients come from south Tamil Nadu. Madurai 
followed by Ramnad districts patients were more  amongst them. Our 
results similar to that of study conducted by Umesh Kapil Et Al. 
 Most of our patients were non-vegetarians taking meat, chicken 
with reused oil in most of the days of the week. They used less green 
leafy vegetables and protective fruits. Skipping of morning breakfast and 
105 
 
late lunch predisposed to gastroesophageal reflux disease. Irregular  dietic 
habits seen in most of the patients. 
 All our  male patients were smokers and alcoholics. The female 
patients were tobacco chewers along with betel nut and betel leaves. 
More than just half of our male patients were also tobacco chewers. Most 
of our patients smoked and consumed  alcohol for more than 30 years. 
The same resluts were observed in India as well as western studies.  
The most common presentation to us was with difficulty in 
breathing, stridor. Nearly half of our patient presented with stridor and 
underwent emergency tracheostomy. Next common presentation was 
change of voice. This is followed by dysphagia, swelling in the neck, 
pain, cough and throat irritation. Almost 2/3 of the patient had significant 
weight loss.  Nearly ¼
th
 of the patients had low haemoglobin level.  Liver 
and renal function tests were normal in all our patients. In the study 
conducted by Shelly Chadha Et al at Delhi, hoarseness of voice was the 
most common symptom. 
Except for few minor abnormalities, chest X-ray  was normal. The 
CT scan was taken in all the patients. 
 The most common tumour staging was stage III followed by stage 
IVa. The most common site involved was supraglottis. The T (tumour) 
staging more of T3,next common was T4a.The nodal staging more 
common was N0 followed by N1.Our study results were similar Shelly 
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Chadha Et al results. Patients presented in advanced stage. They had N2 
as the most common nodal stage, but in our study it was N0. 
 All our patients had squamous cell carcinoma as the 
histopathological diagnosis. The most common histopathological grading 
was moderately differentiated squamous cell carcinoma. This was 
followed by well differentiated squamous cell carcinoma. Both Indian 
studies and western studies had squamous cell carcinoma as the most 
common type of pathology. 
At our hospital all patients received chemoradiotherapy as the 
major modality of the treatment. In four patients palliative radiotherapy 
was offered due to end stage of the disease. The cartilage involvement 
seen in two patients and chemotherapy was offered to them to prevent 
chondronecrosis due to radiotherapy. Most of our patients received 
therapeutic chemoradiotherapy. Kamian Et al supported the radiotherapy 
with or without chemotherapy to all the stages of laryngeal cancers.  
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SUMMARY 
 
 In our study most of them were male patients. The most common age 
group Was 65 years. 
 We had only 4 female patients in our study and all had supraglottic 
growth. 
 All the patients belonged to low socioeconomic strata. 
 The most common part of larynx involved is supraglottis. 
 None of our patients had distant metastasis. 
 The most common presentation was difficulty in breathing and stridor, 
later followed by change of voice and dysphagia. 
 The common histopathological finding was squmous cell carcinoma. 
In that moderatelty differentiated was the most common type. 
 The most common stage was stage III. 
 The most common treatment offered at our hospital was concurrent 
chemoradiotherapy. 
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CONCLUSION 
 
 Cancer larynx is highly preventable disease by avoiding the risk 
factors like tobacco and alcohol.  
 Any patient complaining of change of voice for more than three weeks 
should be investigated thoroughly with videolaryngoscopic 
examination. Especially in an elderly male who is a chronic alcoholic 
and smoker. 
 Curative rates are high in cancer larynx if diagnosed early and treated 
appropriately. 
 Increase in the socioeconomic strata, education level can create 
awareness in the public and to approach near by health care centre for 
change of voice especially in elderly males.  
 Unlike in  the west, supraglottic cancer is common at our hospital. 
 Chemoradiotherapy has made real impact in treatment stratergy. This 
is one of the treatment modality which helps in organ  preservation 
and thus the voice production. Prognosis is poor in later stages of the 
disease. 
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PROFORMA 
Name:                                                  
Age:            
Sex: 
Address: 
Occupation:   
Socioeconomic status:           
Hospital OP No: 
Date of entry into study: 
Informed consent obtained: Yes/ No 
Symptoms: 
Hoarseness of voice: 
Difficulty in swallowing: 
Painful swallowing: 
Irritation/Sore throat: 
Painful Vocalisation: 
Noisy breathing: 
Respiratory distress: 
Heartburn/vomiting: 
Haemoptysis: 
Neck swelling 
Earache: 
Weight loss: 
Cough: 
Onset :Sudden/gradual.         Duration: 
Past history: 
Diabetes mellitus, Hypertension  ,Ischemic heart disease,  
Tuberculosis,syphilis,  Thyroid disorders, Gastroesophageal reflux 
disease. 
Personal history: 
Diet, Appetite, Sleep, Bowel and Bladder habits 
H/o smoking (no. of cigarettes/beedies – in pack years): 
H/o Alcohol intake (amount and duration): 
H/o of betel nut/ pan/ gutka chewing: 
Socio-economic status: 
Exposure to dusty atmosphere/chemical irritants/Fumes: 
Family history: 
Similar complaints in family members: 
Malignancy: 
Clinical Examination: 
General examination: 
Built:good/moderate/poor 
Pallor/Icterus/clubbing/cyanosis/pedal oedema 
Lymph node status:Site/Size/Consistency/mobility 
Systemic Examination: 
Cardiovascular system: 
Respiratory system: 
Per Abdomen: 
Central nervous system: 
ENT Examination: 
Oral cavity: 
Oropharynx: 
Indirect Laryngoscopy: 
Video Laryngoscopy: 
Rigid laryngoscopy and Biopsy: 
Examination of Neck: 
Examination of Ears: 
Examination of Nose and Paranasal sinuses: 
Provisional diagnosis: 
Investigations: 
Blood: Hb/BT/CT/ESR/WBC/Liver function tests 
Chest X-ray/X-ray Neck 
Biopsy: 
CT Scan from Skull base to upper mediastinum: 
Final diagnosis: 
Treatment: 
SL.NO NAME AGE SEX SES PLACE IP NO CHIEF COMPLAINTS PAST HISTORY FAMILY HISTORY PERSONAL HISTORY
1 KULAINDAVEL 70 M CLASS V THIRUMANGALAM 46258 NECK SWELLING,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
2 JANAKI 63 F CLASS V MADURAI 46902 DIFF SWALLOWING,VOICE CHANGE NS NS TOBACCO CHEWER
3 KUPPUSAMY 60 M CLASS V THIRUPATTUR 47916 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
4 SANTHARAM 65 M CLASS V DINDIGUL 49280 DIFF SWALLOWING,VOICE CHANGE NS NS CHR.ALCO,CHR.SMO, TOB CHEW
5 PALANI 70 M CLASS V MADURAI 49689 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
6 SUBRAMANI 55 M CLASS V SHIVAGANGAI 50343 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
7 YESUDAS 60 M CLASS V RAMNAD 50300 NECK SWELLING,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
8 BALAKRISHNAN 56 M CLASS V DINDIGUL 51574 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO, TOB CHEW
9 PERUMAL 65 M CLASS V DINDIGUL 57532 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO, TOB CHEW
10 KARUPPU 48 M CLASS V USLAMPATTI 51771 NECK SWELLING,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
11 RAJARAM 70 M CLASS V RAMANATHAPURAM 51943 NECK SWELLING,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
12 AYYASAMY 76 M CLASS V VIRUDHNAGAR 52375 DIFF SWALLOWING,VOICE CHANGE NS NS CHR.ALCO,CHR.SMO, TOB CHEW
13 SUBRAMANIAN 59 M CLASS V THIRIPURAGUNDRAM 52853 NECK SWELLING,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
14 VIKRAMADITYAN 70 M CLASS V NARAYANAPURAM 52613 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
15 BHASKARAN 47 M CLASS V MADURAI 53929 NECK SWELLING,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
16 KALIAPPAN 62 M CLASS V MADURAI 54887 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
17 SELVARAJ 58 M CLASS V THIRUMANGALAM 54628 DIFF SWALLOWING,VOICE CHANGE NS NS CHR.ALCO,CHR.SMO, TOB CHEW
18 RAMASAMY 70 M CLASS V TUTTUKUDI 55354 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
19 RAJAGOPAL 64 M CLASS V TUTTUKUDI 55620 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
20 SERMAKANNI 65 M CLASS V SHIVAKASI 55892 NECK SWELLING,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
21 MUTHU 65 M CLASS V KORAIKULAM 56922 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
22 MUTTAIAH 60 M CLASS V USLAMPATTI 57218 DIFF SWALL,VOICE CHANGE-6 MTHS NS NS CHR.ALCO,CHR.SMO, TOB CHEW
23 KRISHNAMOORTHY 65 M CLASS V MADURAI 57217 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
24 JAMBULINGAM 63 M CLASS V THENI 57222 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO
25 SHIVAGURUNATHAN 62 M CLASS V MADURAI 57799 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO
26 GANESHAN 55 M CLASS V DINDIGUL 58325 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
27 SHIVAGURUMOORTHI 62 M CLASS V THIRUMANGALAM 58874 NECK SWELLING,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
28 KANDASAMY 64 M CLASS V MADURAI 59403 change of voicedifficulty swallow NS NS CHR.ALCO,CHR.SMO, TOB CHEW
29 KAYAMBU 60 M CLASS V RAMNAD 59569 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
30 SYED ABUDHABI 54 M CLASS V PUDUKOTTAI 60389 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
31 CHINNASAMY 40 M CLASS V MADURAI 61047 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
32 KRISHNAN 63 M CLASS V PARAMAKUDI 62212 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
33 SELVARAJ 55 M CLASS V MADURAI 63891 DIFF SWALLOWING,VOICE CHANGE NS NS CHR.ALCO,CHR.SMO, TOB CHEW
34 RAJU 70 M CLASS V ARUPPUKOTTAI 64783 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
35 MUTTAIAH 60 M CLASS V MADURAI 64898 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
36 RAMAN 70 M CLASS V VIRUDHNAGAR 67146 VOICE CHANGE,DIFFI SWALLOWING HTN,DM NS CHR.ALCO,CHR.SMO, TOB CHEW
37 DHANABHAGYAM 60 M CLASS V MADURAI 59645 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING DM,HTN,CVA NS CHR.ALCO,CHR.SMO
38 RAMAN 62 M CLASS V MADURAI 69018 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
39 DHANUSHKODI 51 M CLASS V VIRUDHNAGAR 68947 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING DM NS CHR.ALCO,CHR.SMO
40 MUTHU 55 M CLASS V DINDIGUL 71933 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
41 VANANGAMUDI 55 M CLASS V MADURAI 72334 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
42 PAALSAMY 60 M CLASS V DINDIGUL 74642 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
43 ARJUNAN 47 M CLASS V SHIVAGANGAI 76849 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
44 VELMURUGAN 38 M CLASS V MADURAI 78934 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
45 KARUPPADEVAR 59 M CLASS V DINDIGUL 80545 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
46 PONUCHAMY 80 M CLASS V MADURAI 82491 NECK SWELLING,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
SL.NO NAME AGE SEX SES PLACE IP NO CHIEF COMPLAINTS PAST HISTORY FAMILY HISTORY PERSONAL HISTORY
47 KANNAN 60 M CLASS V RAMNAD 82735 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
48 VELU 62 M CLASS V RAMNAD 82736 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO, TOB CHEW
49 MUTHU 65 M CLASS V MADURAI 74156 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO, TOB CHEW
50 THANGAVELU 62 M CLASS V MADURAI 83435 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
51 SADAYANDI 65 M CLASS V MADURAI 87387 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO, TOB CHEW
52 KRISHNAN 49 M CLASS V DINDIGUL 87168 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO, TOB CHEW
53 RAJARAMAN 65 M CLASS V MADURAI 85934 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
54 KRISHNAN 56 M CLASS V MADURAI 90773 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
55 KASIPAMBU 62 M CLASS V MADURAI 90752 DIFF SWALL,VOICE CHANGE,NECK SWELLING NS NS CHR.ALCO,CHR.SMO
56 SENTHIL 38 M CLASS V SHIVAGANGAI 93738 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO
57 ANGUSAMY 60 M CLASS V MADURAI 93711 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
58 JAFAR 67 M CLASS V MADURAI 94976 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO, TOB CHEW
59 SETHUPATHI 55 M CLASS V RAMNAD 95396 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO, TOB CHEW
60 GOPAL 63 M CLASS V KARUR 97477 DIFF SWALOW. CHANGE VOICE NS NS CHR.ALCO,CHR.SMO
61 SAKARAI 47 M CLASS V DINDIGUL 97914 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
62 IBRAHIM 60 M CLASS V RAMNAD 93206 change of voicedifficulty swallow NS NS CHR.ALCO,CHR.SMO
63 VILLAN 65 M CLASS V SHIVAGANGAI 92451 change of voicedifficulty swallow NS NS CHR.ALCO,CHR.SMO
64 MARIAYAPPAN 65 M CLASS V SHIVAKASI 93957 NECK SWELLING,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
65 RAJAN 50 M CLASS V KULURNALAI 94975 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
66 IDUMBAN 65 M CLASS V RAMNAD 10983 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
67 LAKSHMANAN 70 M CLASS V MADURAI 11016 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
68 IRULANDI 60 M CLASS V MADURAI 11752 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
69 ADISINGAM 66 M CLASS V SHIVAGANGAI 11793 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
70 RAJAGOPAL 50 M CLASS V RAJAPALYAM 11808 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
71 THANGAPERUMAL 61 M CLASS V VIRUDHNAGAR 13336 change of voicedifficulty swallow NS NS CHR.ALCO,CHR.SMO, TOB CHEW
72 MUTTAIAH 60 M CLASS V MADURAI 14328 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
73 PERUMAL 50 M CLASS V THIRUMANGALAM 13350 change of voicedifficulty swallow NS NS CHR.ALCO,CHR.SMO, TOB CHEW
74 KUMAR 36 M CLASS V MADURAI 15219 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
75 SODALAI 65 M CLASS V MADURAI 16145 change of voicedifficulty swallow NS NS CHR.ALCO,CHR.SMO, TOB CHEW
76 KADALKARAI 40 M CLASS V MADURAI 17613 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
77 RAJENDRAN 74 M CLASS V MADURAI 17655 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
78 CHINNAIAH 47 M CLASS V MADURAI 17899 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
79 AYYANKALI 60 M CLASS V DINDIGUL 14835 change of voicedifficulty swallow NS NS CHR.ALCO,CHR.SMO, TOB CHEW
80 KATTAPULI 50 M CLASS V DINDIGUL 20876 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
81 RAMASAMY 52 M CLASS V MADURAI 21038 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
82 KARNAN 65 M CLASS V MADURAI 21336 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
83 KADARPACHA 74 M CLASS V TRICHY 21223 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
84 SAMUEL 40 M CLASS V MADURAI 21951 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
85 KUPPURAJA 70 M CLASS V DINDIGUL 21977 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
86 MUTHAYEE 70 F CLASS V MADURAI 23305 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS TOBACCO CHEWER
87 GANAPATHY 56 M CLASS V RAMNAD 23325 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO, TOB CHEW
88 JAYAPAL 67 M CLASS V RAMNAD 23297 SWELLING IN NECK,VOICE CHANGE,DIFFI SWAL NS NS CHR.ALCO,CHR.SMO, TOB CHEW
89 KUMARAN 61 M CLASS V MADURAI 23287 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
90 SUBRAMANI 61 M CLASS V DINDIGUL 24007 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
91 MARIYAYEE 53 F CLASS V KARUR 25204 DIFF SWALL,VOICE CHANGE,NECK SWELLING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
92 PALANIVEL 60 M CLASS V KARUR 23953 COUGH,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
SL.NO NAME AGE SEX SES PLACE IP NO CHIEF COMPLAINTS PAST HISTORY FAMILY HISTORY PERSONAL HISTORY
93 MARIAYAPPAN 60 M CLASS V MADURAI 24010 NECK SWELLING,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
94 SUNDARA MAHALINGAM 65 M CLASS V MADURAI 23733 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
95 APPUNATHAN 55 M CLASS V DINDIGUL 26585 SWELLING IN NECK,VOICE CHANGE,DIFFI SWAL NS NS CHR.ALCO,CHR.SMO, TOB CHEW
96 MOHAMMAD ALIYAR 55 M CLASS V DINDIGUL 26031 DIFF SWALL,VOICE CHANGE,NECK SWELLING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
97 KARPAGAM 70 F CLASS V SHIVAGANGAI 26789 SWELLING IN NECK,VOICE CHANGE,DIFFI SWAL NS NS TOBACCO CHEWER
98 VELLAICHAMY 65 M CLASS V RAMNAD 26895 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
99 SADASIVAM 65 M CLASS V MADURAI 26911 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO, TOB CHEW
100 PAULSAMY 63 M CLASS V MADURAI 26978 SWELLING IN NECK,VOICE CHANGE,DIFFI SWALL NS NS CHR.ALCO,CHR.SMO, TOB CHEW
101 veluchamy 68 M CLASS V DINDIGUL 29870 SWELLING IN NECK,VOICE CHANGE,DIFFI SWALL NS NS CHR.ALCO,CHR.SMO, TOB CHEW
102 KANDASAMY 59 M CLASS V KARUR 29910 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO, TOB CHEW
103 JayaPALsamy 65 M CLASS V RAMNAD 30001 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
104 Thanga perumal 70 M CLASS V RAMNAD 30101 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO, TOB CHEW
105 RasuRaman 54 M CLASS V SHIVAGANGAI 30111 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
106 Irullappa pillai 62 M CLASS V TRICHY 30153 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
107 Veeraiah 73 M CLASS V MADURAI 30242 DIFF. SWALLOWING, VOICE CHANGE, NECK SWELLING NS NS CHR.ALCO,CHR.SMO
108 Aavudiyappan 55 M CLASS V THIRUMANGALAM 30312 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
109 Muthu 71 M CLASS V MADURAI 30421 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
110 SundARAm 66 M CLASS V SHIVAGANGAI 30521 CHANGE OF VOICE, DIFFICULTY SWALLOW NS NS CHR.ALCO,CHR.SMO
111 Chellaiah 62 M CLASS V RAMNAD 30614 VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
112 VELLAICHAMY 65 M CLASS V TRICHY 30745 STRIDOR,VOICE CHANGE,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
113 Manian 62 M CLASS V MADURAI 30888 NECK SWELLING,DIFFI SWALLOWING NS NS CHR.ALCO,CHR.SMO
SL.NO NAME AGE SEX
1 KULAINDAVEL 70 M
2 JANAKI 63 F
3 KUPPUSAMY 60 M
4 SANTHARAM 65 M
5 PALANI 70 M
6 SUBRAMANI 55 M
7 YESUDAS 60 M
8 BALAKRISHNAN 56 M
9 PERUMAL 65 M
10 KARUPPU 48 M
11 RAJARAM 70 M
12 AYYASAMY 76 M
13 SUBRAMANIAN 59 M
14 VIKRAMADITYAN 70 M
15 BHASKARAN 47 M
16 KALIAPPAN 62 M
17 SELVARAJ 58 M
18 RAMASAMY 70 M
19 RAJAGOPAL 64 M
20 SERMAKANNI 65 M
21 MUTHU 65 M
22 MUTTAIAH 60 M
23 KRISHNAMOORTHY 65 M
24 JAMBULINGAM 63 M
25 SHIVAGURUNATHAN 62 M
26 GANESHAN 55 M
27 SHIVAGURUMOORTHI 62 M
28 KANDASAMY 64 M
29 KAYAMBU 60 M
30 SYED ABUDHABI 54 M
31 CHINNASAMY 40 M
32 KRISHNAN 63 M
33 SELVARAJ 55 M
34 RAJU 70 M
35 MUTTAIAH 60 M
36 RAMAN 70 M
37 DHANABHAGYAM 60 M
38 RAMAN 62 M
39 DHANUSHKODI 51 M
40 MUTHU 55 M
41 VANANGAMUDI 55 M
42 PAALSAMY 60 M
43 ARJUNAN 47 M
44 VELMURUGAN 38 M
45 KARUPPADEVAR 59 M
46 PONUCHAMY 80 M
GPE SYSTEMIC EXAM VLE EAR NOSE EMER TRAC DLS BIO HPE CHEST X-RAY USG ABD
PALE CREPTS ULCEROPROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
PALE CREPTS PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
PALE CREPTS PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
PALE CREPTS PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
PALE CREPTS PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
PALE CREPTS PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
PALE CREPTS ULCEROPROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
PALE CREPTS ULCEROPROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
PALE CREPTS PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
PALE CREPTS PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
NORMAL CREPTS ULCEROPROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
NORMAL CREPTS ULCEROPROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC EMPHYSEMATOUS LUNGS NORMAL
PALE NORMAL PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SQCC NORMAL NORMAL
PALE NORMAL PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
PALE NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
PALE NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
PALE NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
PALE NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC HYPER INFLA LUNGS NORMAL
PALE CREPTS ULCEROPROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC HYPER INFLA LUNGS NORMAL
PALE CREPTS ULCEROPROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC HYPER INFLA LUNGS NORMAL
PALE CREPTS ULCEROPROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC HYPER INFLA LUNGS NORMAL
PALE CREPTS ULCEROPROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SCC HYPER INFLA LUNGS NORMAL
NORMAL NORMAL ULCEROPROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SQCC NORMAL NORMAL
PALE NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
PALE NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
PALE NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
PALE NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
PALE CREPTS PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC PATCHY PNEMONITIS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC PATCHY PNEMONITIS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SCC PATCHY PNEMONITIS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC PATCHY PNEMONITIS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC PATCHY PNEMONITIS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC PATCHY PNEMONITIS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC PATCHY PNEMONITIS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC PATCHY PNEMONITIS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SQCC PATCHY PNEMONITIS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC PATCHY PNEMONITIS NORMAL
SL.NO NAME AGE SEX
47 KANNAN 60 M
48 VELU 62 M
49 MUTHU 65 M
50 THANGAVELU 62 M
51 SADAYANDI 65 M
52 KRISHNAN 49 M
53 RAJARAMAN 65 M
54 KRISHNAN 56 M
55 KASIPAMBU 62 M
56 SENTHIL 38 M
57 ANGUSAMY 60 M
58 JAFAR 67 M
59 SETHUPATHI 55 M
60 GOPAL 63 M
61 SAKARAI 47 M
62 IBRAHIM 60 M
63 VILLAN 65 M
64 MARIAYAPPAN 65 M
65 RAJAN 50 M
66 IDUMBAN 65 M
67 LAKSHMANAN 70 M
68 IRULANDI 60 M
69 ADISINGAM 66 M
70 RAJAGOPAL 50 M
71 THANGAPERUMAL 61 M
72 MUTTAIAH 60 M
73 PERUMAL 50 M
74 KUMAR 36 M
75 SODALAI 65 M
76 KADALKARAI 40 M
77 RAJENDRAN 74 M
78 CHINNAIAH 47 M
79 AYYANKALI 60 M
80 KATTAPULI 50 M
81 RAMASAMY 52 M
82 KARNAN 65 M
83 KADARPACHA 74 M
84 SAMUEL 40 M
85 KUPPURAJA 70 M
86 MUTHAYEE 70 F
87 GANAPATHY 56 M
88 JAYAPAL 67 M
89 KUMARAN 61 M
90 SUBRAMANI 61 M
91 MARIYAYEE 53 F
92 PALANIVEL 60 M
GPE SYSTEMIC EXAM VLE EAR NOSE EMER TRAC DLS BIO HPE CHEST X-RAY USG ABD
PALE NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
PALE NORMAL PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
PALE NORMAL PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
PALE NORMAL ULCEROPROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
PALE NORMAL ULCEROPROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL ULCEROPROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL ULCEROPROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL ULCEROPROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES POORLY.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC HYPER INFLA LUNGS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SCC HYPER INFLA LUNGS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC HYPER INFLA LUNGS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC HYPER INFLA LUNGS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC HYPER INFLA LUNGS NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES POORLY.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SQCC HYPER INFLA LUNGS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC HYPER INFLA LUNGS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC HYPER INFLA LUNGS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC HYPER INFLA LUNGS NORMAL
NORMAL CREPTS PROL GROWTH NORMAL NORMAL YES YES POORLY.DIFF.SQCC HYPER INFLA LUNGS NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
SL.NO NAME AGE SEX
93 MARIAYAPPAN 60 M
94 SUNDARA MAHALINGAM 65 M
95 APPUNATHAN 55 M
96 MOHAMMAD ALIYAR 55 M
97 KARPAGAM 70 F
98 VELLAICHAMY 65 M
99 SADASIVAM 65 M
100 PAULSAMY 63 M
101 veluchamy 68 M
102 KANDASAMY 59 M
103 JayaPALsamy 65 M
104 Thanga perumal 70 M
105 RasuRaman 54 M
106 Irullappa pillai 62 M
107 Veeraiah 73 M
108 Aavudiyappan 55 M
109 Muthu 71 M
110 SundARAm 66 M
111 Chellaiah 62 M
112 VELLAICHAMY 65 M
113 Manian 62 M
GPE SYSTEMIC EXAM VLE EAR NOSE EMER TRAC DLS BIO HPE CHEST X-RAY USG ABD
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES POORLY.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES POORLY.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES POORLY.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES POORLY.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES POORLY.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL YES YES MOD.DIFF.SQCC NORMAL NORMAL
NORMAL NORMAL PROL GROWTH NORMAL NORMAL NO YES WELL.DIFF.SQCC NORMAL NORMAL
SL.NO NAME AGE SEX
1 KULAINDAVEL 70 M
2 JANAKI 63 F
3 KUPPUSAMY 60 M
4 SANTHARAM 65 M
5 PALANI 70 M
6 SUBRAMANI 55 M
7 YESUDAS 60 M
8 BALAKRISHNAN 56 M
9 PERUMAL 65 M
10 KARUPPU 48 M
11 RAJARAM 70 M
12 AYYASAMY 76 M
13 SUBRAMANIAN 59 M
14 VIKRAMADITYAN 70 M
15 BHASKARAN 47 M
16 KALIAPPAN 62 M
17 SELVARAJ 58 M
18 RAMASAMY 70 M
19 RAJAGOPAL 64 M
20 SERMAKANNI 65 M
21 MUTHU 65 M
22 MUTTAIAH 60 M
23 KRISHNAMOORTHY 65 M
24 JAMBULINGAM 63 M
25 SHIVAGURUNATHAN 62 M
26 GANESHAN 55 M
27 SHIVAGURUMOORTHI 62 M
28 KANDASAMY 64 M
29 KAYAMBU 60 M
30 SYED ABUDHABI 54 M
31 CHINNASAMY 40 M
32 KRISHNAN 63 M
33 SELVARAJ 55 M
34 RAJU 70 M
35 MUTTAIAH 60 M
36 RAMAN 70 M
37 DHANABHAGYAM 60 M
38 RAMAN 62 M
39 DHANUSHKODI 51 M
40 MUTHU 55 M
41 VANANGAMUDI 55 M
42 PAALSAMY 60 M
43 ARJUNAN 47 M
44 VELMURUGAN 38 M
45 KARUPPADEVAR 59 M
46 PONUCHAMY 80 M
CT NECK TNM STAGE DIAGNOSIS TREATMENT FOLLOWUP 1MTH,VLE 2ND MTH,VLE 3RD MTH,VLE
Y t3n1mo stage 3 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n2m0 stage 4a SUPRAGLOTTIC CA CHEMOTHERAPY Y N N N
Y t3n0m0 stage 3 GLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n1m0 stage4a RT.SUPRAGLOTTIC CA PALIATIVE RT Y N N N
Y t2n0m0 stage 2 RT.VOCAL CORD CA CONCURRENT CHEMORT Y N N N
Y t3n1m0 stage 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT EXPIRED  DURING RT
Y t3nom0 stage3 B/L VOCAL CORD CA CONCURRENT CHEMORT WITH HELD
Y t2n1m0 stage 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n0m0 stage 3 GLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t2n1m0 stage3, RT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N1M0 STAGE3 RT.SUPRAGLOTTC CA CONCURRENT CHEMORT OBSCUNDED
Y t3n3m0 stage 4b LT.SUPRAGLOTTIC CA PALIATIVE RT Y N N N
Y t3n1m0 stage 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3nn1m0 stage 3 RT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t2n2m0 stage 4a LT.SUPRAGLOTTIC CA PALIATIVE RT Y N N N
Y t1nomo stage 1 RT.VOCAL CORD CA CONCURRENT CHEMORT Y N N N
Y T3N0M0 STAGE3 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n1m0 stage 3 RT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t2n0m0 stage2 lt glottic ca CONCURRENT CHEMORT Y N N N
Y tt2n1m0 stage 3 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t2n1mo stage3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T2N0M0 STAGE2 RT.SUPRAGLOTTIC CA CONCURRENT CHEMORT OBSCUNDED
Y t3n1m0 stage3 RT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n0m0 stage3 RT.SUPRAGLOTTIC CA CONCURRENT CHEMORT WITH HELD
Y T3NOMO STAGE3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N2M0 stage 4a LT.SUPRAGLOTTIC CA PALIATIVE RT Y N N N
Y t2n2m0 stage4a SUPRAGLOTTIC CA PALIATIVE RT EXPIRED  DURING RT
Y t2n0m0 stage2 RT.GLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3nomo stage 3 SUPRAGLOTTIC CA OBSCUNDED Y N N N
Y tt2n1m0 stage 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t2nomo stage 2 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n2m0 stage4a LT.VOCAL CORD CA PALIATIVE RT Y N N N
Y t3n0m0 stage3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n0m0 STAGE 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3nomo stage3 RT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N1M0 STAGE 3 LT.GLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3nomo stage 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t2nomo stage2 LT.VOCAL CORD CA CONCURRENT CHEMORT Y N N N
Y T3N0MO STAGE3 B/L VOCAL CORD CA CONCURRENT CHEMORT Y N N N
Y t3nomo stage 3 RT.SUPRAGLOTTIC CA CONCURRENT CHEMORT OBSCUNDED
Y t3n0m0 stage3 VOCALCORD CA CONCURRENT CHEMORT Y N N N
Y tt3n1m0 STAGE 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3nomo stage3 LT.VOCAL CORD CA CONCURRENT CHEMORT Y N N N
Y t3n1m0 stage3 RT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N0M0 STAGE3 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N LOST FOLLOWUP
Y t3n2m0 STAGE 4A LT.SUPRAGLOTTIC CA PALIATIVE RT EXPIRED  DURING RT
SL.NO NAME AGE SEX
47 KANNAN 60 M
48 VELU 62 M
49 MUTHU 65 M
50 THANGAVELU 62 M
51 SADAYANDI 65 M
52 KRISHNAN 49 M
53 RAJARAMAN 65 M
54 KRISHNAN 56 M
55 KASIPAMBU 62 M
56 SENTHIL 38 M
57 ANGUSAMY 60 M
58 JAFAR 67 M
59 SETHUPATHI 55 M
60 GOPAL 63 M
61 SAKARAI 47 M
62 IBRAHIM 60 M
63 VILLAN 65 M
64 MARIAYAPPAN 65 M
65 RAJAN 50 M
66 IDUMBAN 65 M
67 LAKSHMANAN 70 M
68 IRULANDI 60 M
69 ADISINGAM 66 M
70 RAJAGOPAL 50 M
71 THANGAPERUMAL 61 M
72 MUTTAIAH 60 M
73 PERUMAL 50 M
74 KUMAR 36 M
75 SODALAI 65 M
76 KADALKARAI 40 M
77 RAJENDRAN 74 M
78 CHINNAIAH 47 M
79 AYYANKALI 60 M
80 KATTAPULI 50 M
81 RAMASAMY 52 M
82 KARNAN 65 M
83 KADARPACHA 74 M
84 SAMUEL 40 M
85 KUPPURAJA 70 M
86 MUTHAYEE 70 F
87 GANAPATHY 56 M
88 JAYAPAL 67 M
89 KUMARAN 61 M
90 SUBRAMANI 61 M
91 MARIYAYEE 53 F
92 PALANIVEL 60 M
CT NECK TNM STAGE DIAGNOSIS TREATMENT FOLLOWUP 1MTH,VLE 2ND MTH,VLE 3RD MTH,VLE
Y t3n0m0 stage 3 RT.VOCAL CORD CA CONCURRENT CHEMORT WITH HELD
Y t3n0m0 stage 3 RT.VOCAL CORD CA CONCURRENT CHEMORT Y N N N
Y T2 N0M0 stage 2 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n0m0 stage3 LT.VOCAL CORD CA CONCURRENT CHEMORT Y N N N
Y t3n1m0 stage 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT WITH HELD
Y t2n0m0 stage 2 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N1M0 STAGE 3 VOCALCORD CA CONCURRENT CHEMORT Y N N N
Y t3nn2m0 stage 4a SUPRAGLOTTIC CA PALIATIVE RT Y N N N
Y T4 N2BM0 STAGE 4A SUPRAGLOTTIC CA PALIATIVE RT EXPIRED  DURING RT
Y T3N1M0 STAGE 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n1m0 stge 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t2n0m0 stage2 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3 n0m0 stage 3 rt glottic growth CONCURRENT CHEMORT Y N N N
Y t3 n0m0 stage3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3NOMO STAGE3 LT.GLOTTIC CA CONCURRENT CHEMORT Y LOST FOLLOWUP
Y t2n0m0 stage 2 LT.GLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n1mo stage3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n2m0 stage4a LT.SUPRAGLOTTIC CA PALIATIVE RT Y N N N
Y t3n0m0 stage3 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N1M0 STAGE3 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT OBSCUNDED
Y T3N2BMX STAGE 4A SUPRAGLOTTIC CA PALIATIVE RT Y N N N
Y t3n0m0 stage3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n1m0 stage3 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3NOMO STAGE3 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n0m0 stage3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N0M0 STAGE3 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T2NOMO STAGE2 rt sg growth CONCURRENT CHEMORT Y N N N
Y T3N2M0 STAGE 4A SUPRAGLOTTIC CA PALIATIVE RT Y N N N
Y T3NOMO STAGE 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N1M0 STAGE3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N1M0 STAGE 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N1MX STAGE 3 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n0m0 stage 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n0m0 stage3 RT.VOCAL CORD CA CONCURRENT CHEMORT Y N N N
Y t3n1m0 stage 3 RT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N LOST FOLLOWUP
Y t3n0m0 stage3 RT.VOCAL CORD CA CONCURRENT CHEMORT OBSCUNDED
Y T4AN2M0 STAGE4A LT.VOCAL CORD CA CHEMOTHERAPY Y N N N
Y t3n1m0 stage3 B/L SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n1m0 stage 3 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N1MX STAGE 3 RT.VOCAL CORD CA PALIATIVE RT Y N N N
Y t3n1m0 stage 3 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N3MX stage4b LT.SUPRAGLOTTIC CA CHEMOTHERAPY Y N N N
Y t3n1m0 stage3 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n0m0 stage3 RT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N1MX STAGE 3 B/L SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n0m0 stage3 LT.VOCAL CORD CA CONCURRENT CHEMORT Y N N N
SL.NO NAME AGE SEX
93 MARIAYAPPAN 60 M
94 SUNDARA MAHALINGAM 65 M
95 APPUNATHAN 55 M
96 MOHAMMAD ALIYAR 55 M
97 KARPAGAM 70 F
98 VELLAICHAMY 65 M
99 SADASIVAM 65 M
100 PAULSAMY 63 M
101 veluchamy 68 M
102 KANDASAMY 59 M
103 JayaPALsamy 65 M
104 Thanga perumal 70 M
105 RasuRaman 54 M
106 Irullappa pillai 62 M
107 Veeraiah 73 M
108 Aavudiyappan 55 M
109 Muthu 71 M
110 SundARAm 66 M
111 Chellaiah 62 M
112 VELLAICHAMY 65 M
113 Manian 62 M
CT NECK TNM STAGE DIAGNOSIS TREATMENT FOLLOWUP 1MTH,VLE 2ND MTH,VLE 3RD MTH,VLE
Y T3N3MX STAGE 4B LT.SUPRAGLOTTIC CA CHEMOTHERAPY Y N N N
Y t3n0m0 stage3 RT.VOCAL CORD CA CONCURRENT CHEMORT Y N N N
Y T3N2BMX STAGE 4A RT.SUPRAGLOTTIC CA CHEMOTHERAPY Y N N N
Y T3N1MX STAGE 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N3M0 stage4b RT.SUPRAGLOTTIC CA CHEMOTHERAPY Y N LOST FOLLOWUP
Y T3NOMO STAGE 3 SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t2n0m0 STAGE 2 LT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T3N2M0 stage 4a RT.SUPRAGLOTTIC CA CONCURRENT CHEMORT Y N N N
Y t3n2m0 stage 4a bil supraglottic CONCURRENT CHEMORT Y N N N
Y T3N0M0 STAGE3 bil glottic CONCURRENT CHEMORT Y N N N
Y T3N2BMX STAGE 4A SUPRAGLOTTIC GROWTH CONCURRENT CHEMORT Y N N N
Y T3N2BMX STAGE 4A bil sg growth CONCURRENT CHEMORT Y N N N
Y t3n0m0 stage3 lt glottic ca CONCURRENT CHEMORT Y N N N
Y t3n0m0 stage3 RT.GLOTTIC GROWTH CONCURRENT CHEMORT OBSCUNDED
Y t2n0m0 stage2 LT.GLOTTIC CA CONCURRENT CHEMORT Y N N N
Y T4AN1MX STAGE 4A SUPRAGLOTTIC GROWTH CONCURRENT CHEMORT Y N N N
Y T3N0M0 STAGE3 SUPRAGLOTTIC GROWTH CONCURRENT CHEMORT Y N N N
Y T2NOMO STAGE 2 RT.GLOTTIC GROWTH CONCURRENT CHEMORT Y N N N
Y T3N3M0 stage4b RT.SUPRAGLOTTIC CONCURRENT CHEMORT Y LOST FOLLOWUP
Y T3N0M0 STAGE3 BIL.GLOTTIC GROWTH CONCURRENT CHEMORT Y N N N
Y t3n2m0 stage4a RT.SUPRAGLOTTIC CONCURRENT CHEMORT Y N N N
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SWALL  = SWALLOWING 
TOB   = TOBACCO 
Y   = YES 
 
010
20
30
40
50
60
31-40 41-50 51-60 61-70 71-80
MALES
FEMALES
NO OF PATIENTS
MALE
FEMAILE
AGE AT DIAGNOSIS 
N 
O 
of 
P 
A 
T 
I 
E 
N 
T 
S 
AGE IN YEAR 
 
SEX INCIDENCE 
 
 
M = 109        F = 4 
 
 
 
 
 
 
 
020
40
60
80
100
120
SMOKING ALCOHOL TOBACCO
MALE
FEMALE
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
MALES
FEMALES
HABITS 
N 
O 
of 
P 
A 
T  
I 
E 
N 
T 
S 
HABITS 
 
SYMPTOMS 
% 
of 
P 
A 
T 
I 
E 
N 
T 
S 
SYMPTOMS 
 
0
5
10
15
20
25
30
35
40
MALE
FEMALE
0
10
20
30
40
50
60
70
WELL DIFF MOD DIFF POORLY DIFF
MALE
FEMALE
TOPOGRAPHICAL REPRESENTATION 
N 
O 
of 
P 
A 
T 
I 
E 
N 
T 
S 
SUBSITES 
 
HISTOPATHOLOGY 
N 
O 
of 
P 
A 
T 
I 
E 
N 
T 
S 
HISTOPATHOLOGY 
010
20
30
40
50
60
N0 N1 N2a N2b N2c N3
MALE
FEMALE
T STAGING 
N 
O 
of 
P 
A 
T 
I 
E 
N 
T 
S 
T STAGING 
 
N – STAGING 
N 
O 
of 
P 
A 
T 
I 
E 
N 
T 
S 
N – STAGING 
0
10
20
30
40
50
60
70
80
90
T1
T2
T3
T4a
MALE
FEMALE
010
20
30
40
50
60
70
80
STAGE 0 STAGE I STAGE II STAGE III STAGE IVa STAGE  IVb
MALE
FEMALE
0
10
20
30
40
50
60
DONE
NOT DONE
MALE
FEMALE
TNM STAGING 
N 
O 
of 
P 
A 
T 
I 
E 
N 
T 
S 
TNM STAGING 
 
TRACHEOSTOMY 
N 
O 
of 
P 
A 
T 
I 
E 
N 
T 
S 
TRACHEOSTOMY 
0 20 40 60 80 100
CONCURRENT CHEMORT
PALLIATIVE RT
CHEMOTHERAPY
FEMALE
MALE
TREATMENT GIVEN 
T 
R 
E 
A 
T 
M 
E 
N 
T 
 
NO of PATIENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
SUPRAGLOTTIC SCC T3N1M0 
STAGE III 
  
COBALT 60 
 
 
 
 
 
 
 
 
 
 
  
WELL DIFFERENTIATED SCC 
 
 
 
POORLY DIFFERENTIATED SCC 
 
 
THE LARYNX 
 
 
 
 
 CERVICAL  LYMPHNODES 
 
 
 
 
Submission author:
Assignment title:
Submission title:
File name:
File size:
Page count:
Word count:
Character count:
Submission date:
Submission ID:
Digital Receipt
This receipt acknowledges that Turnitin received your paper. Below you will find the receipt information
regarding your submission.
The first page of your submissions is displayed below.
221314103.ms (ent). Dr.Suman A P
TNMGRMU EXAMINATIONS
A CLINICOPATHOLOGICAL STUDY…
FINAL.docx
119.25K
115
18,124
100,428
23-Sep-2014 04:33AM
453336265
Copyright 2014 Turnitin. All rights reserved.
